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Abstract
The combination of cardiovascular and metabolic risk factors including obesity,
dyslipidemia, hypertension, and insulin resistance, in combination with a prothrombotic
and proinflammatory state, is a condition termed Metabolic Syndrome (METS). Twenty
percent of the adult population is afflicted with METS which increases the risk of type-2
diabetes mellitus and cardiovascular disease. Further, the presence of peripheral vascular
disease (PVD) is tightly coupled with METS which is a perfusion-demand mismatch of
blood supply to active skeletal muscle resulting in painful claudication and a late-stage
potential for amputation. The underlying contributors of METS associated microvasculopathies in the skeletal muscle, their impact on impaired perfusion, and the
potential for reversibility remain unclear. Owing its hyperphagia to leptin signaling
resistance, the obese Zucker rat (OZR) is a translationally relevant model for human
METS and the associated micro-vasculopathies. The overall purpose of this thesis is to
utilize a multi-scale approach, particularly intravital microscopy and isolate vessels, to
garner a greater understanding of the observed OZR vasculopathies and to investigate the
potential of therapeutic interventions for their reversibility.
Project 1: The purpose was to identify any alterations in postcapillary and collecting
venule function in the OZR compared to healthy controls. The OZR presented with
impaired dilator reactivity and elevation in thromboxane A2 constrictor responses for
both postcapillary and collecting venules.
Project 2: The purpose was to identify the possible contributors of a disconnect for in-situ
and ex-vivo vascular studies utilizing the OZR model. Using a multi-scale approach,
Project 2 provides insight to this disconnect and reveals a heterogenous adrenergic
I

response in the OZR, giving rise to new potential avenues of study.
Project 3: The purpose was to determine the potential for reversibility or restoration of
established PVD using the chronic ingestion of an HMG-CoA inhibitor, atorvastatin,
and/or the implementation of regular exercise. Following a seven-week intervention, the
intervention groups revealed vascular improvements with the combination group having
the greatest capacity for reversibility (in specific indices).
Significance: Therefore, this thesis further advances the understanding of METS
associated PVD as well as potential modes for improvement following its establishment.
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Chapter 1
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Introduction and Review of the Literature
Metabolic Syndrome (METS) is a myriad of cardiovascular disease and metabolic

disease risk factors including obesity, dyslipidemia, hypertension, and insulin
resistance/impaired glycemic control tightly coupled with the presence of prothrombotic
and proinflammatory physiological states (Frisbee & Delp, 2006). The Adult Treatment
Panel III defines individuals with METS as having 3 of the following 5 criteria:
abdominal obesity (waist circumference: men >102 cm and women >88 cm), elevated
triglycerides (≥ 1.7 mmol/L), reduced HDL cholesterol (men<1.04 mmol/L and
female<1.30 mmol/L), elevated blood pressure (≥130/≥85 mmHg), and elevated fasting
glucose (≥6.1 mmol/L).

1.1 Metabolic Syndrome
One in five adults between the ages of 18-79 are afflicted with METS (Riediger &
Clara, 2011) which increases the risk of chronic diseases such as type II diabetes mellitus
(T2DM) and cardiovascular disease (CVD) by approximately 5-fold and 2.6-fold,
respectively (Grundy et al., 2002; Lakka, 2002). CVD is defined by The American Heart
Association as the presentation of poor heart function and/or inadequate blood supply to
tissues/organ systems (AHA, 2017) and T2DM is a metabolic disease characterized by
insulin resistance and impaired glycemic utilization for energy thereby starving working
cells (ADA, 2015). Further, the resulting hyperglycemia may cause detrimental injuries
to the eyes, heart, kidneys, and nerves (ADA, 2015). The World Health Organization
reports CVD as the world’s leading cause of death and T2DM is ranked 7th (WHO,
2018). More specifically, CVD and T2DM remain significant contributors to Canadian
mortality rates, accounting for a combined 17% of all health care costs and 43% of all
deaths in Canada (MetSC, 2018; Heron, 2007). While METS may serve as a critical
precursor for these chronic diseases, detrimental changes to peripheral vascular
circulation, both structurally and functionally, are observed in parallel to the onset and
progression of METS (Alberti et al., 2009; Chantler & Frisbee, 2015).
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A critical consequence of METS on the peripheral vasculature includes the
reduction of blood supply and perfusion to working skeletal muscle (McClatchey et al.,
2017). Healthy, active muscles produce vasoactive, metabolic byproducts which promote
increases in blood flow and perfusion to meet the increased metabolic demand of the
working muscle. This physiological process is termed hyperemic response. Both human
and animal models have revealed a decreased hyperemic response, despite similar muscle
phenotypes, with METS compared to healthy controls (Jacqueline et al., 2016; Guarini et
al., 2016). Further supported by both in-vivo and ex-vivo studies, the blunted hyperemic
responses observed with METS and inflammation is a result of pathophysiological
alterations in vessel dilation and constriction, vascular densities, and structural
compositions (both atherogenic and non-atherogenic changes) all which will be covered
with greater detail in subsequent sections (Butcher et al., 2013; Frisbee et al., 2009).
Taken together, this supply/demand mismatching and its associated symptoms is known
as peripheral vascular disease (PVD).
Pathophysiological alterations to the skeletal muscle may result in PVD which is
independently associated with increases in CVD morbidity and mortality (Paraskevas et
al. 2010) and that risk is further augmented when coupled with METS (Katsiki et al.,
2013; Wassink et al., 2018; Czel & Tefan, 2006). The National Health and Nutrition
Examination Survey reported 38.4% of adults with METS, over the age of 40, were
diagnosed with PVD (Sumner et al., 2012). Individuals afflicted with PVD may
experience leg muscle fatigue, cramps, and pain during bouts of physical activity and, in
the more extreme cases of vascular insufficiency when supply/demand mismatching
occurs at rest, ulceration or gangrene of the feet may occur with a potential for limb
amputation (Abdulhannan et al., 2012). Without revascularization, patients with vascular
insufficiency will have a 19% risk of amputation within the first 6 months of initial
treatment and 23% risk at one year (Marston et al., 2006).
The Obese Zucker Rat as a Translational Model for Metabolic Syndrome
All of the material presented thus far has mainly been emphasized on
epidemiological observations. While technology and public health records enable us to
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non-invasively evaluate the broader outcomes of metabolic syndrome in humans, more
invasive measures using animal models are essential to further investigate the
vasculopathologies with greater control and detail. Most human studies introduce
confounding variables such as genetic variations between patients. Albeit, these
confounding variables may exist in animal models, but the ability to manipulate,
measure, and control for their presence and/or severity is more feasible in utilizing this
animal model.
The obese Zucker rat (OZR; fa/fa) is a translationally relevant model for
examining metabolic syndrome. When co-expressed, the autosomal recessive mutation,
fa, located on chromosome 5 causes a coding error for the leptin receptor gene, thereby
producing an amino acid substitution on the leptin receptors and reducing leptin binding
to the cerebral cell surface receptors in the choroid plexus and lateral ventricles of the
brain (Yarnell et al., 1997; Kurtz, Morris, & Pershadsingh, 1989). Leptin is a key
regulating hormone for energy consumption. Produced by the adipose tissue in proportion
to fat storage, leptin is released into the circulatory system and interacts with the brain’s
leptin receptors to signal for a decrease in consumption and an increase in energy
expenditure (Halaas et al., 1995). As such, the OZR exhibits an impaired satiety reflex
resulting in chronic hyperphagia which leads to the onset of excess body fat as early as 34 weeks of life and, by week 14, approximately 40%-50% of the rat’s total body weight is
adipose tissue while healthy controls from the same litter are measured at approximately
20% (Artinano & Castro, 2009; Cleary et al., 1980). This rapid onset and progression of
obesity is paralleled by increases in insulin resistance, dyslipidemia, hyperglycemia, and
hypertension (Kurtz, Morris, & Pershadsingh, 1989).
Both humans with METS and the OZR experience similar systemic pathologies as
well as prolonged periods of hypertriglyceridemia and insulin resistance prior to the overt
development of type II diabetes mellitus (Frisbee & Delp, 2006). Further, the OZR
demonstrates clinically relevant mild to moderate hypertension, which is comparable to
the severity observed in humans with METS (Johnson et al., 2006) as well as a
proinflammatory and prothrombotic state (Vaziri et al., 2005; Frisbee & Delp, 2006).
Therefore, when considering the consistent parameters and the similar progression of
3

those parameters to that of the human conditions, the OZR represents an ideal
translational model for garnering a greater understanding of METS.

1.2 Biophysical Consequences
Although the cardiovascular system is essential for physiological functions such
as oxygen and nutrient delivery to the body’s tissues, thermoregulation, combating
diseases, and the clearance of metabolites and carbon dioxide from tissues, its most basic
description includes that of a fluid (i.e. blood) transport system. As such, blood flow can
be described using Ohm’s Law for fluids where flow (Q) is equal to the change in driving
pressure (P) generated by the heart divided by the resistance (R).
Q=ΔP/R
Further, blood flow in a single vessel of the cardiovascular system can be
determined via Poiseuille’s Law where the change in pressure across the vessel is
multiplied by radius (r) then divided by the vessels length (l) and blood viscosity (η).
R=8ηl/ πr4

Q=(ΔPπr4)/8ηl

Due to radius being heavily weighted in the context of fluid/blood resistance, a
50% decrease in lumen diameter will yield a 16-fold increase in resistance. Therefore,
radius is a key determinant for fluid resistance and flow in the vasculature.
In the dynamic cardiovascular system, vessel radii, mainly at the arteriolar level,
is regulated via both intrinsic and extrinsic signals. Extrinsic systems such as metabolic
signals, circulating hormones, and the sympathetic nervous innervation provide external
regulatory signaling to the vasculature based on the needs of the supplied tissues.
Intrinsic mechanisms such as myogenic control and shear stress further regulate vessel
diameter based on intralumenal pressure and shear rate of blood against the lumen walls
of the vessel, respectively. The range of vasodilator/constrictive responses may vary
depending on the level of vasculature being interrogated such as the arteries, arterioles
and their sub-units (Al-Khazraji et al. 2015; Chilian et al., 1989). However, the general
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premise of these vascular controllers is to regulate vessel radii via vasoconstriction and
vasodilation, dependent on the metabolic needs of perfused tissues.
In the presence of obesity, dyslipidemia, and impaired glycemic control, the
vascular dilator and constrictor responses in the skeletal muscle are altered to favor that
of a decrease in vessel radius at rest and in response to both extrinsic and intrinsic
controllers compared to healthy controls. In accordance with Ohm’s Law for Fluids and
Poiseuille’s Law, a system which favors a vasoconstrictive state, thereby decreasing radii
and increasing resistance, will result in a proportional increase in blood pressure and/or a
decrease in flow. This insufficiency in blood supply to tissues during higher metabolic
demand can contribute to myocardial infarctions, stroke, and intermittent claudication
with a potential to result in limb amputation. Biological contributors to these biophysical
consequences involved in decreased vessel radii compared to healthy controls will be
further defined in subsequent sections. Additionally, insulin resistance and the resulting
hyperinsulinemia (Wu et al., 2000) can exert hypertrophic effects on vascular smooth
muscle cells (i.e. vessel proliferation) and promote atherogenic monocyte adhesion and
infiltration (Yeh, 2004). These pathologies can decrease vessel radii (Hutcheson et al.,
2014; Cersosimo et al., 2014) as well as cause decreases in vessel wall deformation
(Chantler & Frisbee, 2015) thereby further limiting skeletal muscle perfusion (Fossum et
al., 1998).
While temporal regulatory dysfunction of the arterioles is a key contributor
toward increases in blood flow resistance in the skeletal muscle vasculature of those with
METS, there are detrimental spatial alterations as well. The Frisbee lab reported
significant reductions in microvessel densities (i.e. vascular rarefaction) within the
gastrocnemius muscle of OZR compared to healthy controls (Frisbee, 2003) and
reductions in vessel density have been shown to exert the largest effect on tissue oxygen
levels (Greene et al., 1992). As such, tissues of high metabolic demand, but reduced
densities may result in reduced oxygen levels which could limit the metabolic activity
and performance of that tissue (Greene et al., 1992). Optimal capillary-to-tissue
(cylinder) density ratio for sufficient oxygen diffusion across tissues can be described
using the Krogh Cylinder Model (Krogh, 1919) with respect to the partial pressure
5

gradient of O2 (Fig. 1-A). In this model, decreases in capillary density, in the absence of
compensatory alterations in tissue density, can shift this optimal ratio and create areas of
hypoxia as the cylinder becomes too large for the diffusion of O2 across tissue (Fig. 1-B).
Figure 1-A: Krogh Cylinder Model describing optimal capillary/tissue ratio and O2
diffusion to surrounding tissue

(Graphic retrieved from PerfusionTheory.com; link in 1.7)
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Figure 1-B: Krogh Cylinder Model describing suboptimal capillary/tissue ratios and
resulting areas of hypoxia

(Graphic retrieved from PerfusionTheory.com; link in 1.7)
In addition to implications on gas and nutrient delivery/clearance to the perfused
tissue, rarefaction can promote increases in overall network resistance (Greene et al.,
1989). Figure 2 describes the decrease in the overall resistance (arbitrary numbers) for
vessels oriented in parallel to an overall value lower than that of any single vessel within
the network and how that overall resistance will increase if one of the parallel vessels is
removed, if other variables remain constant. Therefore, vessels in parallel decrease the
overall network resistance and reducing the number of vessels in parallel will increase the
overall resistance of a network. In the context of METS, fifteen-week-old OZRs have a
20-25% reduction in microvessel density (Frisbee, 2003) which can promote both
increases in network resistance and decreases in oxygen delivery thereby contributing to
reduced blood flow and oxygenation of working skeletal muscles.
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Figure 2: Example of increases in network resistance with decreases in parallel vessels
(arbitrary units).

Metabolic syndrome is associated with various biophysical consequences such as
shifted lumen diameters in response to pharmacological and/or muscle stimulation which
favors a more vasoconstrictive state compared to healthy controls. Coupled with
structural changes and rarefaction, there is a multitude of factors that increase vascular
resistance and decrease muscle perfusion thereby contributing to the high prevalence of
PVD with METS. Although most of microcirculatory research interrogates the arterial
side, previous studies show the earliest changes in vascular dysfunction can be observed
on the venular side of skeletal muscle networks with an emphasis on retrograde
rarefaction from the venules to the arterioles (Frisbee et al., 2014). Some of the
contributing pathologies of these biophysical consequences are covered in the following
sections, with respect to the context of this dissertation.
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1.3 Biological Contributors to Biophysical Detriments
While biophysical detriments associated with METS contribute to the obstruction
and reduction of blood flow to perfused skeletal muscles, the cause of these detriments
are rooted in the biological pathologies linked with obesity, impaired glycemic control,
and dyslipidemia. This dissertation will explore some of those pathologies and their
contributions to increases in vascular resistance on both the arteriole side and the venular
side of the microcirculation in the OZR. Further, we will explore interventional and
treatment strategies for reversing these pathological contributors with the primary goals
of decreasing vascular resistance, increasing tissue perfusion, and increasing
microvascular density.
Endothelial nitric oxide
Endothelial dysfunction is a key vascular consequence of METS and chronic
inflammation, by which there is a decrease in nitric oxide (NO) bioavailability compared
to healthy controls under both resting and stimulated conditions. In short, NO is an
essential molecule which signals for vascular smooth muscle relaxation/dilation which is
produced in the endothelium and can be stimulated via acetylcholine, bradykinin, and/or
the shear stress created by blood flow against the endothelial wall which up regulates
intracellular calcium release to activate the NO synthesizing enzyme, endothelial nitric
oxide synthase (eNOS; Fig. 3). Following this, eNOS converts L-arginine to L-citrulline
and synthesizes NO which diffuses out of the endothelial cell to the neighboring vascular
smooth muscle to dephosphorylate guanine triphosphate to elicit vasodilation and prevent
smooth muscle proliferation/remodeling thereby promoting decreases in vascular
resistance and vessel stiffening, respectively. However, the reduced NO bioavailability
associated with METS can shift the vasculature to a more vasoconstrictive state, thus
increasing vascular resistance which is a key contributor to elevated blood pressure and
hypertension. Furthermore, clot formation and leukocyte recruitment are both inhibited
by NO (Hossain et al., 2012), therefore the decrease in NO bioavailability with METS
can contribute to the observed prothrombotic and proinflammatory state.

9

Figure 3: Endothelial nitric oxide production

Proinflammation and oxidative stress
While the presence of a proinflammatory state are reliably associated with METS
(Ford, 2003), they are not typically considered inclusion criteria for the clinical diagnosis
of METS. However, both human and animal models with metabolic syndrome risk
factors consistently report evidence of elevated markers including, but not limited to
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and c-reactive protein (CRP), all of
which can be attributed to excess fat stores (Goodwill, 2008; Ford, 2003; Erdembileg et
al., 2015; Bickel et al., 2002). TNF-α cytokines can impact endothelial function (Singer
and Granger, 2007), increase reactive oxygen species (ROS) production (Agharazii et al.,
2015), alter glucose metabolism of the skeletal muscle via the inhibition of insulin
receptor tyrosine kinase (Hotamisligil et al., 1996), promote smooth muscle cell
proliferation, and increase monocyte cell adhesion and infiltration (Yeh, 2004). IL-6 is a
key regulator for CRP production which is a clinical marker of inflammation that serves
as an early predictor for cardiovascular disease, including asymptomatic patients (Ridker
et al., 2002). Elevated CRP mediated activity can directly inhibit nitric oxide (NO)
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production via inhibition of eNOS and endothelial dysfunction (Jialal, 2009) and
contribute to the elevated levels of ROS production associated with a pro-inflammatory
state (Prasad, 2004; Singer and Granger, 2007).
ROS is a chemically reactive byproduct of oxidative metabolism which is
essential for cell signaling, immune response, as well as non-pathological apoptosis and
contain one or more oxygen atoms and unpaired electrons. The highly reactive
superoxide anion (O2-·) is the initial ROS produced by mitochondrial metabolism which
is normally and rapidly transformed into H2O2 and then to water via the antioxidant
enzymes superoxide dismutase (SOD) and catalase/glutathione peroxidase, respectively.
However, oxidative stress, or elevations in ROS production beyond that of endogenous
antioxidant systems, can result in the alteration of essential cellular proteins and increases
in proteolytic susceptibly (Davies et al., 1986). There are a multitude of studies
connecting oxidative stress with observed vasculopathies associated with impaired
glycemic control and insulin resistance, cardiovascular diseases, and a multitude of other
diseases (Agharazii et al., 2015; Frisbee & Delp, 2006; Davies et al., 1986). A key
consequence of excess ROS in the context of vascular function is its reactivity with
endothelial derived NO to form elevated levels of peroxynitrate, which can uncouple
eNOS, thus decreasing both the production and the bioavailability of NO (Fig 4;
Goodwill and Frisbee, 2012).
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Figure 4: Superoxide pathways

Additionally, vascular necrosis/rarefaction can be linked to increased oxidative
stress as NO is essential for the structural maintenance of the vasculature and
angiogenesis (Cooke and Losordo, 2002). Decreases in vascular density may lead to
increases in hypoxia which can further exacerbate ROS production and contribute to a
self-perpetuating pathology (Chandel et al., 1998). Taken together, ROS production is a
self-propagating phenomenon which is detrimental to normal cellular function. In the
context of this dissertation, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL), a
free radical scavenger and superoxide mimetic, is used to measure the contribution of
ROS on the blunted dilatory response of the OZR vasculature compared to healthy
controls.
An additional consequence includes a ratio shift in prostacyclin (PGI2) and
thromboxane (TxA2) production attributed mainly to oxidative stress (Goodwill et al,
2008), dyslipidemia, and the oxidization of low density lipoproteins (Palinski et al. 1989;
Pfister & Campbell, 1996). PGI2 and TxA2 are two well known, vasoactive end products
of arachidonic acid (AA) metabolism by cyclooxygenase to prostaglandin endoperoxide
H2 (Figure 5: AA metabolism). PGI2 and TxA2 are known to elicit opposite actions on
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coagulation and vasodilatory/vasoconstrictive response. PGI2 is recognized more so as
the homeostatic product of AA metabolism as it promotes vasodilation and has anticoagulant properties, whereas TxA2 is a potent vasoconstrictor which promotes red blood
cell and platelet aggregation and is more so observed at the sight of acute injuries or in
pathophysiological conditions.
Figure 5: Arachidonic acid metabolism cascade

In the presence of insulin resistance there is a shift in arachidonic acid metabolism
which favors TxA2 production (Hishinuma, 2001) which has been attributed to the
inactivation of prostacyclin synthase via interaction with the elevated levels of
peroxynitrite (Davis & Zou, 2005). Further, it has been suggested impaired glycemic
control may promote protein kinase C activity with ensuing increases in the inducible
isoform, cyclooxygenase-2, activity to produce elevated TXA2 production in circulating
leukocytes (Nusing et al., 1993). This shift promotes a more vasoconstrictive state of the
vessels at rest and in response to the TXA2 mimetic U46619 (Goodwill, 2008) thereby
decreasing the lumen size and contributing to increases in vascular resistance.
Additionally, the coagulative actions of TXA2 promotes the prothrombic state observed
with METS risk factors which increases the risk of clot/thrombotic formations and
associated diseases and detrimental cardiovascular events such as stroke and heart attack.
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Adrenergic Control
The altered vasodilatory signaling and reactivity observed with METS and models
of METS is well established. Previous studies have also demonstrated the decrease in
skeletal muscle lumen diameter in the OZR can be further credited to an elevated
constrictor response to sympathetic nervous system (SNS) innervation compared to
healthy controls (Stepp & Frisbee, 2002). The SNS elicits vasoconstriction via the release
neuronal signals and the interaction with their respective receptors (R) which includes the
following: nor-adrenaline (α1-R & α2-R; adrenergic), adenosine triphosphate (P2X1-R;
purinergic), and neuropeptide Y (Y1-R; peptidergic). Vascular responses to these signals
within the arteriole microcirculation experience heterogeneous distribution where
proximal arterioles are largely under adrenergic control and the distal arterioles are more
so under purinergic and/or peptidergic control (Anderson & Faber, 1991; Al-Khazraji et
al. 2015).
It has been suggested the decreases in hyperemic response to occlusion and the
more vasoconstricted state observed in OZR may be attributed to the augmentation of α1adrenergic response, validated by the rescuing effects of adrenergic blockers such as
prazosin and phentolamine (Frisbee, 2006). This dissertation will examine the αadrenergic response observed using a mutli-scale (in-situ, in-vivo, and ex-vivo) approach
at various levels of microcirculation (feed arteries, arterioles, terminal/precapillary
arteries) to garner a greater understanding of the variability observed when using single
point interrogations at a single level of the vasculature. While the majority of previous
research in the context of microcirculation and blood flow resistance has focused on the
interrogation of arteries and resistance arterioles, we also examine the effects of αadrenergic mediation of venule diameters to identify potential contributors to the overall
increase in vascular resistance observed in METS and METS models.
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1.4 Translational Interventions for PVD: Chronic Exercise
and/or HMG-CoA Reductase Inhibitor
An existing clinical and translational disparity in animal models with METS
associated PVD is that many of the employed interventions are relevant for blunting the
severity of vasculopathies of the developing PVD. However, from a clinical stance, this
may not serve as the most relevant model as many patients seek medical assistance due to
claudication or pain in their extremities when performing physical activity, meaning PVD
is already well established. Therefore, animal studies which employ early interventions,
prior to the establishment of PVD, are not translationally relevant for humans presenting
with established PVD. In the context of this dissertation, we employ interventions
following the establishment of PVD which includes regular, physical activity/exercise
and/or the chronic ingestion of the HMG-CoA inhibitor, atorvastatin.
Chronic Exercise
It is well established that regular exercise can improve obesity, insulin resistance,
and dyslipidemia in both humans and animals (Moller & Kaufman, 2005; BeckerZimmermann et al., 1982). Additionally, exercise has been shown to improve vascular
densities in skeletal muscle, both trained/locomotive muscles (Frisbee, 2006) and nontrained/systemic muscles (Qui et al., 2018), and improves NO bioavailability (Machado
et al., 2016). NO bioavailability plays a critical role in angiogenic incompetence and
rarefaction (Machado et al., 2016; Ungvari et al., 2018) and this dependency has been
suggested to be the major underlying mechanism of microvascular rarefaction in METS
(Frisbee, 2005).
A multitude of previous studies indicate improvements in NO bioavailability via
increases in eNOS expression and activity for both healthy controls (Parker et al., 2011)
and disease states (Orr et al., 2009; Fiuza-Luces et al., 2018). A potential contributor to
this upregulation may be in adaptation to the regular increases of exercise induced shear
stress from blood flow, a potent stimulus for NO production and vasodilation (Fleming
and Busse, 2003). Improvements in NO bioavailability are paralleled by decreases in
ROS generation and improvements in antioxidant systems (Kojda & Hambrecht, 2005).
15

Potential mechanisms include increases in superoxide dismutase, catalase, and peroxidase
(Berzosa et al., 2011) as well as decreases in the NADPH oxidase production of ROS
(Rush et al., 2003). Taken together, these exercise-induced improvements can result in
increases of NO bioavailability in METS models thereby promoting angiogenesis to
combat rarefaction and improve many of the other previously listed pathologies
associated with impaired NO bioavailability.
HMG-CoA Inhibition
Clinically, the inhibition of liver enzyme 3-hydroxy-3-methylglutaryl coenzyme
A reductase (HMG-CoA) is commonly used in an effort to reduce circulating cholesterol
levels, thus the target for cholesterol lowering drugs such as the HMG-CoA reductase
inhibitor, atorvastatin (ATOR). However, statins also have pleiotropic effects and are
therefore increasingly used for reasons beyond lowering cholesterol levels, including
anti-inflammation (Fujita et al., 2007). Although the mechanisms are unclear, statins are
associated with improvements in inflammatory markers and endothelial cell function
which result in better outcomes of inflammation-linked vascular diseases (HaslingerLöffler, 2008). More specifically, ATOR has been reported to decrease the expression of
the previously mentioned inflammatory cytokines (IL-6 and TNF-α), decrease CRP, and
improve defense systems against reactive oxygen species (Rabkin et al., 2013; Sodha et
al., 2015) thus improving the previously mentioned, associated detriments observed with
established PVD.

1.5 Specific Aims
1. To determine alterations for post-capillary venular structure/function in OZR and the
extent this contributes to elevated network resistance and impaired mass
transport/exchange. These experiments employ intravital imaging of in situ skeletal
muscle with specific physiological and pharmacological challenges to determine venular
hemodynamic and vasomotor diameter responses in METS.

2. To determine the role of adrenergic signaling and its interaction with altered
endothelial function on resistance in pre-capillary, arteriolar networks of OZR and how it
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may contribute to skeletal muscle perfusion. These experiments employ in vivo, in situ,
and ex vivo conditions to interrogate interactions between adrenergic responses and their
influence on vessel diameters.

3. To determine the potential for reversibility of OZR microvasculopathies using exercise
and atorvastatin. These experiments employ intravital microscopy of in situ skeletal
muscle and the study of ex vivo arterioles to determine alterations in vessel diameter
control, blood flow distribution, and bulk perfusion within arteriolar networks.

1.6 Significance
METS and PVD continue to burden the health of afflicted individuals via
decreases in quality of life and increases in both morbidity and mortality. Further, these
burdens extend to higher healthcare spending. Although strides have been made to
understand these diseases, many of the underlying mechanisms remain unclear.
Therefore, this dissertation seeks to further advance the understanding of METS
associated PVD and explore potential modes for improvement following its
establishment.
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KEY POINTS:
•

With the development of the metabolic syndrome, both post-capillary and collecting
venular dilator reactivity within the skeletal muscle of obese Zucker rats (OZR) is
impaired.

•

The impaired dilator reactivity in OZR reflects a loss in venular nitric oxide and PGI2
bioavailability, associated with the chronic elevation in oxidant stress.

•

Additionally, with the impaired dilator responses, a modest increase in adrenergic
constriction, combined with an elevated thromboxane A2 production may contribute
to impaired functional dilator and hyperemic responses at the venular level.

•

The shift in skeletal muscle venular function with development of the metabolic
syndrome on issues such as aggregate microvascular perfusion resistance, mass
transport and exchange within with capillary networks, and fluid handling across the
microcirculation are compelling avenues for future investigation.
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2.1 Abstract
While research into vascular outcomes of the metabolic syndrome has focused on
arterial/arteriolar and capillary levels, investigation into venular function and how this
impacts responses has received little attention. Using the in situ cremaster muscle of
obese Zucker rats (OZR; with leans (LZR) as controls), we determined indices of venular
function. At ~17 weeks of age, skeletal muscle post-capillary venular density was
reduced by ~20% in LZR vs. OZR, although there was no evidence of remodeling of the
venular wall. Venular tone at ~25 µm (post-capillary) and ~75 µm (collecting) diameter
was elevated in OZR vs. LZR. Venular dilation to acetylcholine was blunted in OZR vs.
LZR due to increased oxidant stress-based loss of nitric oxide bioavailability (postcapillary) and increased α1- (and α2-) mediated constrictor tone (collecting). Venular
constrictor responses in OZR were comparable to LZR for most stimuli, although
constriction to α1 adrenoreceptor stimulation was elevated. In response to field
stimulation of the cremaster muscle (0.5, 1, 3 Hz), venular dilator and hyperemic
responses to lower frequencies were blunted in OZR, but responses at 3 Hz were similar
between strains. Venous production of TxA2 was higher in OZR than LZR and
significantly higher than PGI2 production in either following arachidonic acid challenge.
These results suggest that multi-faceted alterations to skeletal muscle venular function in
OZR may contribute to alterations in upstream capillary pressure profiles and the transcapillary exchange of solutes and water under conditions of metabolic syndrome.
Key words: venous function, microcirculation, metabolic syndrome, skeletal muscle
blood flow
Abbreviations: DPEP IV, dipeptidyl peptidase-4; GS-1, griffonia simplicifolia 1; LNAME, Nω-Nitro-L-arginine methyl ester hydrochloride; LZR, lean Zucker rat; OZR,
obese Zucker rat; PGI2, prostacyclin; TEMPOL, 4-hydroxy-2,2,6,6-tetramethylpiperidin1-oxyl; TxA2, thromboxane A2
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2.2 Introduction
It is well established that the growing incidence and prevalence of the metabolic
syndrome presents a consistent threat to aggregate public health cardiovascular outcomes
across many societies and developed economies (Mameli et al., 2017; Tune et al., 2017;
Vassalo et al., 2016). This syndrome is broadly defined as the combined presentation of
obesity, impaired glycemic control, atherogenic dyslipidemia and hypertension, with the
additional contributing conditions of pro-oxidant, pro-thrombotic and pro-inflammatory
phenotypes (American Heart Association, 2017; Vassalo et al., 2016). While this
condition is present in a growing number of afflicted persons worldwide, its influence on
morbidity and mortality (Global Burden of Metabolic Risk Factors for Chronic Diseases
Collaboration, 2014), as well as the economic costs that must be borne by society
(Shamsedden et al., 2011; Trasande and Elbel, 2012), mandate the detailed investigation
into this multi-pathology state.
While enormous investment has been made in understanding the impact of the
metabolic syndrome on arterial/arteriolar and capillary function (Goodwill et al., 2012,
Lemaster et al., 2017, Tune et al. 2017), dedicated study of venular function has been
limited and has largely focused on leukocyte-endothelial cell interactions as well as
inflammatory and pro-thrombotic processes (Estato et al., 2017; Iba et al., 2012; Scallan
et al., 2015). Although these are important aspects of altered venular function, our
understanding of venous tone regulation and its potential contribution to integrated
microvascular function through the transition from health to disease is far from complete.
Population health studies, using the retinal microcirculation as a “window” into altered
venular function, suggest that the control of venular diameter and venular network
structure can be significantly altered with metabolic disease (Lammert et al., 2012; Wong
et al., 2004; Zhao et al., 2012). However, there has been a limited attempt at
investigating these relationships in relevant animal models.
The obese Zucker rat (OZR; fa/fa) represents a translationally-relevant model to
study the metabolic syndrome, as cardiovascular disease in this model tracks well with
cardiovascular (dys)function in afflicted humans. OZR develop the metabolic syndrome
due to chronic hyperphagia based in leptin resistance, and rapidly develop all of the
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systemic phenotypes listed above to comparable levels of severity to that commonly
identified in human subjects. Also similar to the health outcomes in humans, OZR
exhibiting the metabolic syndrome suffer from a progressive vasculopathy that ultimately
develops into overt peripheral vascular disease (Frisbee and Delp, 2006), albeit one
without the development of significant atherosclerotic lesions. While there has been
extensive interrogation of the impact of metabolic syndrome on the arterial side of the
microcirculation in OZR and in comparable models (Tune et al., 2017), there has been
less effort devoted to understanding the potential for altered venular function under these
conditions and the potential impact on integrated microvascular function.
The purpose of the present study was to begin to understand how the function of in situ
post-capillary and collecting venules from obese Zucker rats manifesting the full
metabolic syndrome can be impacted as a result of the multi-pathology state. To assess
this, we used an array of physiological and pharmacological challenges to understand
how function is altered at these two levels within the venular networks. The present
study tested the hypothesis that post-capillary and collecting venular function in the in
situ skeletal muscle of OZR is altered in a manner that can increase venular blood flow
resistance and negatively impact function within the capillary networks.

2.3 Materials and Methods
Ethical Approval: All procedures in the present study had received prior review and
approval by the Institutional Animal Care and Use Committee. All animal use procedures,
including anesthesia and euthanasia, conform to standards established by the UK/European
Union legislation (set out in in ASPA Schedule 1 in the UK and in Annex IV in the
European Directive 2010/63/EU), the Canadian Council for Animal Care and the United
States Department of Agriculture. All details of animal use are provided in the subsequent
paragraphs.
Animals: Male lean (LZR, Harlan/Envigo) and obese Zucker rats (OZR, Harlan/Envigo)
were acquired at 6-7 weeks of age, and after one week of acclimation, were aged to ~17
weeks of age. All animals were fed standard chow and tap water ad libitum for all
experiments. On the experiment day, after an 8 hour fast, rats were anesthetized with
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injections of sodium pentobarbital (50 mg•kg-1 i.p.), and all rats received tracheal intubation
to facilitate maintenance of a patent airway. In all rats a carotid artery and an external
jugular vein were cannulated for determination of arterial pressure and for intravenous
infusion of additional substances as necessary (e.g., anesthesia, heparin, etc.). Any animal
in which mean arterial pressure was found to be below 85 mmHg (<5% in both LZR and
OZR), or where it had decreased by more than 15% from that following equilibration
(without any pharmacological intervention; ~5% in LZR, ~10% in OZR) was not used in the
present study. Blood samples were drawn from the venous cannula for determination of
glucose and insulin concentrations (Millipore, Billerica, MA) as well as
cholesterol/triglyceride levels (Wako Diagnostics, Richmond, VA), and nitrotyrosine (Oxis
International. Foster City, CA). Blood gases were determined using a Corning RapidLab
248 Blood Gas Analyzer (Siemens Medical Solutions, Malvern, PA). Unless otherwise
noted, all drugs and chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Adequate depth of anesthesia was confirmed at ~15 minute intervals by monitoring
ventilation patterns and noting an absence of whisker movement, startle and toe-pinch
withdrawal reflexes. Additional anesthetic was introduced in 10 mg•kg-1 increments, as
needed, through the jugular vein cannula. After all experiments, the anesthetized rat was
euthanized with an intravenous overdose of sodium pentobarbital (>200 mg•kg-1) followed
by a bilateral pneumothoracotomy and physical removal of the heart. Due to the lasting
effects of some of the pharmacological interventions and the inherent difficulties in
reversing them, not all observations could be gathered from every animal. As a result, in
specific experiment groups, the actual number of animals used can exceed the number of
specific observations. This was done in order to preserve quality and experiment rigor. For
clarity, total animal numbers used for the present study, and their distribution across the
experimental groups, are summarized in Table 1.
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Table 1. Animal numbers, experimental group distributions and condition observation
numbers within groups for the present study. All other experiment data came from ex
vivo tissue analyses recovered from within these animal groups. Please see text for
details.
LZR

OZR

Animals

Observations

Animals

Observations

Experiment Group 1

6

6

8

8

Experiment Group 2

12

6

12

6

Experiment Group 3

12

6

12

6

Experiment Group 4

6

6

8

8

Experiment Group 5

5

5

5

5

Total Animal Number

41

---

45

---

Preparation of In Situ Cremaster Muscle: In each rat, the left cremaster muscle was
prepared for television microscopy (Butcher et al., 2013). After completion of the
preparation, the cremaster muscle was superfused with PSS, equilibrated with a gas mixture
containing 5% CO2 and 95% N2, and maintained at 35C as it flowed over the muscle. The
ionic composition of the PSS was as follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6,
NaH2PO4 1.18, MgSO4 1.17, and NaHCO3 24.0. Venular diameter was determined with an
on-screen video micrometer. After an initial post-surgical equilibration period of 30
minutes, venules of two sizes, ~75 µm diameter; (“collecting”) and ~25 m diameter (“postcapillary”) were selected for investigation in a clearly visible region of the muscle. Venules
selected for study had walls that were clearly visible, a brisk flow velocity, and active tone,
as indicated by the occurrence of significant dilation in response to topical application of 105

M adenosine. All venules studied were located in a region of the muscle that was away

from any incision. In all experiments, at the conclusion of all procedures, 10-3 M adenosine
and 10-3 M sodium nitroprusside were added to the superfusate to determine maximal
diameter of the monitored venules.
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Experiments Group 1:

These experiments were designed to determine fundamental

cremaster muscle venular responses to pharmacological stimuli between LZR and OZR.
Following an equilibration period, the responses of selected venules within the cremaster
muscle of LZR and OZR were assessed in response to increasing concentrations of
acetylcholine (10-10 – 10-6 M), phenylephrine (α1 adrenoreceptor agonist; 10-10 – 10-6 M),
clonidine (α2 adrenoreceptor agonist, 10-10 – 10-6 M), angiotensin II (vasoconstrictor
peptide, 10-10 – 10-6 M), endothelin (vasoconstrictor peptide, 10-10 – 10-6 M) or
acetylcholine (endothelium-dependent dilator, 10-10 – 10-6 M).
Experiments Group 2: These experiments determined basic signaling mechanisms that can
contribute to the alterations in dilator reactivity to acetylcholine and the constrictor reactivity
to phenylephrine determined between LZR and OZR in Group 1. For these experiments,
following the determination of baseline responses to acetylcholine and phenylephrine (as
above), the cremaster muscle was treated with L-NAME (nitric oxide synthase inhibitor; 10-4
M), indomethacin (cyclooxygenase inhibitor; 10-5 M), TEMPOL (cell-permeable antioxidant;
10-4 M) or SQ-29548 (PGH2/TxA2 receptor antagonist, 10-5 M). As in our previous studies
(Butcher et al., 2013; Frisbee et al., 2014), to exert maximum effectiveness, each inhibitor
was applied for at least 45 minutes prior to evaluation of venular reactivity.
In a subset of animals from Experiment Groups 1 and 2, the cremaster muscle of LZR
(n=10) and OZR (n=10) was treated with prazosin (α1 adrenoreceptor blocker, 10-5 M),
yohimbine (α2 adrenoreceptor blocker, 10-5 M), or both and constrictor responses to
norepinephrine (10-10 – 10-6 M) were determined to assess any differences in receptor
contribution between the strains.
Experiments Group 3: These experiments determined basic signaling mechanisms that
contribute to acetylcholine-induced dilation or phenylephrine-induced constriction of
cremaster muscle venules of LZR and OZR following pretreatment with 10-4 M TEMPOL.
Following incubation with the antioxidant, venular responses to increasing concentrations of
acetylcholine and phenylephrine were assessed under the new “control” conditions, and
following treatment of the muscle with L-NAME, indomethacin, or SQ-29548, as described
above.
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Experiment Group 4: These experiments determined the responses of in situ cremaster
muscle venules of LZR and OZR in response to increased metabolic demand. Contraction of
the cremaster muscle was evoked by three minutes of electrical field stimulation at 0.5, 1 or 3
Hz (400 ms duration, 60 Hz within train, 7V; Grass SD 48). At the conclusion of the muscle
contraction period, venular diameter and center-line erythrocyte velocity (optical Doppler
velocimeter, Texas A&M University, College Station, TX) were determined and used for the
calculation of hyperemic responses (see below).
Experiment Group 5: These experiments determined the degree of leukocyte adhesion and
rolling on the post-capillary venular endothelium between LZR and OZR. In a separate
cohort of LZR and OZR, the in situ extensor digitorum longus muscle was prepared as
described previously (Frisbee et al., 2014; Tyml and Budreau, 1991).

Following

preparation of the muscle for imaging, 10 random high magnification fields of view (PlanNeo 20x/0.5 and 40x/0.75; Zeiss) were recorded using a high-speed cooled digital imaging
system (Axiocam HSm; Zeiss) for later analyses. Animals received a bolus injection of
rhodamine 6G (0.3 mg/kg; Sigma) to permit visualization of leukocytes. Rhodamine 6Glabeled vascular cells were visualized by epi-illumination at 510-560 nm, using a 590-nm
emission filter. The number of rolling and adherent leukocytes in venules was expressed
as cells/mm2 of endothelial surface, calculated from the diameter and length of the venular
segment. Leukocytes were considered adherent if they remained stationary for a 30 second
observation period. Leukocytes were considered rolling if their velocity was less than 250
μm/sec (Zeintl et al., 1989).
Histological Determination of Microvessel Density: From LZR and OZR that were
selected from each of the above groups, the gastrocnemius muscle from the left leg was
removed, rinsed in PSS and fixed in 0.25% formalin. Muscles were embedded in paraffin
and cut into 5 µm cross sections. Sections were incubated with Griffonia simplicifolia I
lectin (GS-1) and dipeptidylpeptidase IV (DPEP IV), for subsequent determination of
microvessel density. GS-1 is a general stain that labels all microvessels <20 µm in diameter
(Greene et al., 1990) and DPEP IV preferentially stains venular ends of capillaries
(Mrázková et al., 1986). Labeled microvessel density was determined using fluorescent
(for GS-1) or light microscopy (for DPEP IV) as described previously (Frisbee et al., 2014).
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Determination of Vascular Metabolites of Arachidonic Acid: Vascular production of 6keto-prostaglandin F1α(6-keto-PGF1α; the stable breakdown product of PGI2; Liu et al., 1997;
Nies 1986), and 11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma
breakdown product of TxA2; Catella et al., 1986) in response to challenge with arachidonic
acid (10-6 M) was assessed using pooled conduit veins (e.g., femoral, saphenous) from LZR
and OZR. Pooled vessels from each animal were incubated in microcentrifuge tubes in 1 ml
of physiological salt solution for 30 minutes under control conditions (21% O2 with the
arachidonic acid challenge). After this time, the superfusate was removed, stored in a new
microcentrifuge tube and frozen in liquid N2, while a new aliquot of PSS with arachidonic
acid was added to the vessels for the subsequent 30 minutes. After the second 30 minute
period, this PSS was transferred to a fresh tube, frozen in liquid N2 and stored at -80C.
Metabolite release by the vessels was determined using commercially available EIA kits for
6-keto-PGF1 and 11-dehydro-TxB2 (Cayman).
Data and Statistical Analyses: Blood flow in venular segments within in situ cremaster
muscle of LZR and OZR was calculated as:
𝑄 = (𝑉 × 1.6−1 )(𝜋𝑟 2 )(0.001)
where Q represents venular perfusion (nl•s-1), V represents the measured red cell velocity
from the optical Doppler velocimeter (mm•s-1; with V/1.6 representing an estimated
average velocity assuming a parabolic flow profile; Baker and Wayland, 1974), and r
represents venular radius (µm; Davis, 1987).
All data are presented as mean±SD. Statistically significant differences in measured
and calculated parameters between LZR and OZR in the present study were determined using
repeated measures analysis of variance (RM-ANOVA), where agonist concentration or
muscle stimulation frequency were used as the repeated measures. Statistically significant
differences in arachidonic acid metabolite production, leukocyte adhesion/rolling and
measures of microvessel density between LZR and OZR were assessed using standard
ANOVA or Student’s t-test, as appropriate. Student-Newman-Keuls post hoc test was used
when appropriate and p<0.05 was taken to reflect statistical significance.
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2.4

Results

At ~17 weeks, OZR exhibited all aspects of the metabolic syndrome, being obese as
compared to age-matched LZR, with impaired glycemic control, dyslipidemia in both
cholesterol and triglyceride levels, with a moderate level of hypertension (Table 2). In
addition, OZR exhibited both a chronic level of oxidant stress within the vasculature as well
as a chronic state of inflammation. Within the in situ cremaster muscle, venular diameters
under untreated conditions demonstrated a modest reduction in diameter in OZR as compared
to LZR, and there was no difference in venular diameter under passive conditions. When
taken together, however, calculated active tone of in situ venules for OZR in the post-capillary
level, but not in the collecting venules, was elevated as compared to that for LZR.
Table 2. Baseline characteristics (mean±SD) of ~17 week old LZR and OZR used in the present study. * p<0.05 versus LZR.

LZR

OZR

Mass (g)

35859

67971*

MAP (mmHg)

98±21

129±35*

[Glucose]plasma (mg/dl)

105±49

164±65*

[Insulin]plasma (ng/ml)

1.4±1.1

7.6±6.0*

[Cholesterol]plasma (mg/dl)

84±38

132±65*

[Triglycerides]plasma (mg/dl)

91±53

361±118*

[Nitrotyrosine]plasma (ng/ml)

11±16

44±36*

[TNF-]plasma (pg/ml)

2.1±1.6

7.4±4.7*

[MCP-1]plasma (pg/ml)

32±27

94±47*
Post-Capillary Venules

Resting Diameter (m)

21±11

19±12

Maximum/Passive Diameter (m)

36±16

37±18

Active Tone (%)

40±17

49±17*
Collecting Venules

Resting Diameter (m)

66±17

62±18

Maximum/Passive Diameter (m)

105±21

107±24

Active Tone (%)

37±16

42±18
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Figure 1 summarizes post-capillary venular dilator responses (to acetylcholine, Panel
A) or constrictor responses (to endothelin, Panel B; angiotensin II, Panel C; clonidine, Panel
D; or phenylephrine, Panel E). In response to increasing concentrations of acetylcholine,
dilator responses of both distal and proximal venules of OZR were attenuated as compared to
responses in LZR. Venules from OZR and LZR all demonstrated a robust constriction in
response to increasing concentrations of endothelin, angiotensin II and clonidine (Panels BD), although there were no demonstrable differences in these responses between strains.
However, venular constrictor responses to increasing concentrations of the 1 adrenoreceptor
agonist phenylephrine were significantly increased in OZR over the mid-range of the agonist
challenge (Panel E).

Figure 1. Data describing the reactivity of post-capillary venules within in situ cremaster muscle of LZR and OZR in response
to increasing concentrations of acetylcholine (Panel A), endothelin (Panel B), angiotensin II (Panel C), clonidine (Panel D)
and phenylephrine (Panel E). Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage
of the initial resting state (~ 25 m). * represents p<0.05 versus responses from LZR at that agonist concentration. Results
and determination of statistically significant difference represent n=6 observations from 6 animals in LZR; n=8 observations
from 8 animals in OZR.

Data describing the reactivity of collecting venules within the in situ cremaster muscle
of LZR and OZR are presented in Figure 2. As with the smaller venules, dilator responses of
larger collecting venules to acetylcholine were attenuated in OZR as compared to responses
in LZR (Panel A), while responses to increasing concentrations of endothelin (Panel B) and
angiotensin II (Panel C) were comparable. However, while venular constrictor responses to
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phenylephrine were enhanced in OZR as compared to LZR (Panel D), responses to clonidine
(Panel E) were also increased versus those in LZR.

Figure 2. Data describing the reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response
to increasing concentrations of acetylcholine (Panel A), endothelin (Panel B), angiotensin II (Panel C), clonidine (Panel D)
and phenylephrine (Panel E). Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage
of the initial resting state (~ 70 m). * represents p<0.05 versus responses from LZR at that agonist concentration. Results
and determination of statistically significant difference represent n=6 observations from 6 animals in LZR; n=8 observations
from 8 animals in OZR.

Figure 3 presents the mechanistic contributors to the venular dilation to acetylcholine
in post-capillary venules of LZR (Panels A and C) and OZR (Panels B and D). In LZR, dilator
responses of venules to increasing concentrations of acetylcholine were largely nitric oxidedependent, as treatment with L-NAME significantly attenuated responses (Panel A). While
there was a contribution from cyclooxygenase products to this response, it was less substantial
than that for nitric oxide.

In OZR, the attenuated venular dilation to acetylcholine was

abolished following treatment of the cremaster muscle with L-NAME, but only minimally
impacted as a result of treatment with indomethacin. However, incubation of the tissue with
TEMPOL resulted in a more robust dilation to increasing concentrations of acetylcholine
(Panel B). If the cremaster muscle of LZR or OZR was incubated with TEMPOL prior to
challenge with increasing concentrations of acetylcholine, these relationships were not
fundamentally altered in venules of LZR (Panel C). However, the improvement in the
acetylcholine-induced venular dilation in OZR was abolished by L-NAME, unaffected by
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indomethacin, and mildly improved by blockade of PGH2/TxA2 receptors with SQ-29548
(Panel D).

Figure 3. The dilator reactivity of post-capillary venules within in situ cremaster muscle of LZR and OZR in response to
increasing concentrations of acetylcholine (Panels A and B, respectively). Data are presented for venular reactivity under
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or
TEMPOL. For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals
in OZR. Also presented are data describing the reactivity of post-capillary venules following pre-treatment with TEMPOL in
LZR and OZR (Panels C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME,
indomethacin (INDO) or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH2/TxA2 to
reactivity. Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage of the initial resting
state (~ 25 m). * represents p<0.05 versus responses from LZR at that agonist concentration. For Panels C and D, results
represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals in OZR. All statistical analyses were
done on the number of observations within the group, not the number of animals within the group. Please see text and Table
1 for details.

The relationships between acetylcholine-induced dilation (with or without pretreatment with TEMPOL) and its basic mechanistic contributors were consistent in the larger
collecting venules within in situ cremaster muscle of LZR and OZR with some exceptions
(Figure 4, Panels A-D). In post-capillary venules from LZR and OZR rats and in collecting
venules from OZR, indomethacin did not have a demonstrable impact on dilator responses
to acetylcholine, but significantly attenuated collecting venular dilation in LZR. Further,
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the indomethacin-sensitive component of the collecting venular dilation to acetylcholine
was absent in OZR and in LZR and OZR pre-treated with TEMPOL.

Figure 4. The dilator reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response to
increasing concentrations of acetylcholine (Panels A and B, respectively). Data are presented for venular reactivity under
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or
TEMPOL. For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals
in OZR. Also presented are data describing the reactivity of collecting venules following pre-treatment with TEMPOL to
normalize responses in OZR (Panels C and D, respectively), where the cremaster muscle was subsequently treated with LNAME, indomethacin (INDO) or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or
PGH2/TxA2 to reactivity. Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage of
the initial resting state (~ 70 m). * represents p<0.05 versus responses from LZR at that agonist concentration. For Panels
C and D, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals in OZR. All statistical
analyses were done on the number of observations within the group, not the number of animals within the group. Please see
text and Table 1 for details.

Using prazosin (1 adrenergic receptor blocker) and yohimbine (2 adrenergic
receptor blocker), alone and in combination, the constrictor responses of post-capillary and
collecting venules within cremaster muscle of LZR and OZR in response to increasing
concentrations of norepinephrine were demonstrated to be almost entirely 1-receptordependent in postcapillary venules and predominantly 1-receptor dependent (with a smaller
contribution from 2 adrenergic receptors) in collecting venules in both strains (data not
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shown). Data describing the interaction of altered endothelial function and the venular
constriction to increasing concentration of norepinephrine are summarized in Figure 5. In the
immediate post-capillary venules, treatment of the cremaster muscle with L-NAME increased
constrictor responses to norepinephrine in LZR (Panel A), but was without effect in OZR
(Panel B). While treatment with indomethacin was largely without effect in either strain,
treatment of the muscle with TEMPOL had only a minor effect on venular responses in LZR,
but attenuated the constrictor response in OZR venules. Following pre-treatment of the
cremaster muscle with TEMPOL in LZR, responses to increasing concentrations of
norepinephrine and the impact of L-NAME, indomethacin and SQ-29548 were similar to that
determined under untreated conditions (Panel C). In contrast, pre-treatment of the cremaster
muscle of OZR with TEMPOL (moderating the severity of the norepinephrine-induced
constriction), shifted venular reactivity such that constrictor responses were increased
following treatment with L-NAME, were unaffected by indomethacin, but were reduced
following additional treatment with SQ-29548 (Panel D). Comparable to the responses to
acetylcholine challenge, these relationships between norepinephrine-induced venular
constriction (with or without pre-treatment with TEMPOL) and its basic contributors were
similar in the collecting venules within in situ cremaster muscle of LZR and OZR (Figure 6,
Panels A-D).
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Figure 5. The constrictor reactivity of post-capillary venules within in situ cremaster muscle of LZR and OZR in response to
increasing concentrations of norepinephrine (Panels A and B, respectively). Data are presented for venular reactivity under
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or
TEMPOL. For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals
in OZR. Also presented are data describing the reactivity of post-capillary venules following pre-treatment with TEMPOL
(Panels C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME, indomethacin (INDO)
or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH2/TxA2 to reactivity. Data are
presented as the mean (±SD) change in venular inner diameter, expressed as a percentage of the initial resting state (~ 25 m).
* represents p<0.05 versus responses from LZR at that agonist concentration. For Panels C and D, results represent n=6
observations from 12 animals in LZR; n=6 observations from 12 animals in OZR. All statistical analyses were done on the
number of observations within the group, not the number of animals within the group. Please see text and Table 1 for details.
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Figure 6. The constrictor reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response to
increasing concentrations of norepinephrine (Panels A and B, respectively). Data are presented for venular reactivity under
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or
TEMPOL. For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals
in OZR. Also presented are data describing the reactivity of collecting venules following pre-treatment with TEMPOL (Panels
C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME, indomethacin (INDO) or SQ29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH2/TxA2 to reactivity. Data are presented as
the mean (±SD) change in venular inner diameter, expressed as a percentage of the initial resting state (~ 70 m). * represents
p<0.05 versus responses from LZR at that agonist concentration. For Panels C and D, results represent n=6 observations from
12 animals in LZR; n=6 observations from 12 animals in OZR. All statistical analyses were done on the number of
observations within the group, not the number of animals within the group. Please see text and Table 1 for details.

In response to field stimulation of the in situ cremaster muscle of LZR and OZR at
increasing metabolic demand, the dilator and perfusion responses of post-capillary and
collecting venules are summarized in Figure 7. In response to increasing metabolic demand,
the dilator responses of post-capillary (Panel A) and collecting (Panel B) cremaster muscle
venules was attenuated at the low (0.5 Hz) and moderate (1.0 Hz) contraction frequencies, but
was similar at the high (2.0 Hz) contraction frequency. Perfusion responses followed a similar
pattern, exhibiting a restrained hyperemic response at the lower two contraction frequencies
in both post-capillary (Panel C) and collecting (Panel D) venules, that was not present at the
high contraction frequency.
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Figure 7. The responses of venules within in situ cremaster muscle of LZR and OZR in response to increasing metabolic
demand, imposed via field stimulation across the muscle. Dilator responses to elevated metabolic demand are presented for
post-capillary and collecting venules in Panels A and B, respectively; while functional hyperemic responses are presented in
Panels C and D, respectively. Data (mean±SD) are presented for venular responses, expressed as a percentage of values at the
initial resting state. * represents p<0.05 versus responses from LZR at that stimulation frequency. Results represent n=6
observations from 6 animals in LZR; n=8 observations from 8 animals in OZR. All statistical analyses were done on the
number of observations within the group, not the number of animals within the group. Please see text and Table 1 for details.

Pre-treatment of the cremaster muscle with TEMPOL moderated this difference in
metabolism-induced venular dilation in the post-capillary venules of OZR, but had no
significant effect on the dilator responses to muscle contraction in the larger collecting venules
(Figure 8, Panels A and B). A similar impact was determined on blood flow responses, where
hyperemia was improved in both venular diameter ranges, although responses in the larger
venules failed to achieve statistical significance (Panels C and D). In contrast, pre-treatment
of the cremaster muscle with phentolamine (1/2 adrenoreceptor blocker) had minimal
impact on contraction-induced dilation or perfusion in post-capillary venules (Panels A and
C), although both the dilator and hyperemic responses were improved in the larger collecting
venules (Panels B and D).
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Figure 8. The responses of venules within in situ cremaster muscle of LZR and OZR in response to increasing metabolic
demand, imposed via field stimulation across the muscle. Dilator responses to elevated metabolic demand are presented for
post-capillary and collecting venules in Panels A and B, respectively; while functional hyperemic responses are presented in
Panels C and D, respectively. Data (mean±SD) are presented under control conditions for each strain, and following pretreatment of the cremaster muscle (from OZR only) with TEMPOL or phentolamine. All data are expressed as a percentage
of values at the initial resting state. * represents p<0.05 versus responses from LZR at that stimulation frequency. Results
represent n=6 observations from 6 animals in LZR; n=8 observations from 8 animals in OZR. All statistical analyses were
done on the number of observations within the group, not the number of animals within the group. Please see text and Table
1 for details.

The venous production of PGI2 and TxA2 in response to challenge with arachidonic
acid is summarized in Figure 9. Venous PGI2 production, estimated from the levels of 6-ketoPGF1, was reduced in OZR as compared to levels in LZR under control conditions (Panel
A). Pre-treatment of the pooled veins with TEMPOL had no effect on responses in LZR, but
resulted in an increase in the production of PGI2 in OZR. In contrast, venous production of
TxA2, estimated from the levels of 11-dehydro-TxB2, was elevated in OZR vs. LZR under
control conditions (Panel B), but was reduced toward levels determine in LZR following pretreatment of veins with TEMPOL. Venous production of either PGI2 or TxA2 was abolished
following treatment of the vessels with indomethacin.
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Figure 9. Venous production of 6-keto-PGF1 (from PGI2; Panel A) and 11-dehydro-TxB2 (from TxA2; Panel B) following
challenge with arachidonic acid in pooled vessels from LZR and OZR. Data (mean±SD) are presented under control conditions
for each strain, and following pre-treatment of the pooled vessels with either TEMPOL or indomethacin (INDO). * represents
p<0.05 versus responses from LZR within the treatment group. Results represent n=6 observations from 6 animals in LZR;
n=6 observations from 6 animals in OZR. All tissues for these ex vivo experiments were taken from animals within
Experimental Groups 1 and 2. Please see text for details.

Data describing the adhesion and rolling of leukocytes in the post-capillary venules of
the in situ extensor digitorum longus muscle of LZR and OZR are summarized in Figure 10.
For both adhesion of leukocytes and rolling of adherent cells, responses were increased in the
networks of OZR as compared to that for LZR.
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Figure 10. Data describing the adhesion and rolling of leukocytes in the post-capillary venules of in situ extensor digitorum
longus muscle of LZR and OZR. Rhodamine 6G-labeled vascular cells were visualized by epi-illumination and the number
of rolling and adherent leukocytes in venules was expressed as number of cells/are of endothelial surface, calculated from the
diameter and length of the venular segment. * represents p<0.05 vs. LZR. Results represent n=5 observations from 5 animals
in LZR; n=5 observations from 5 animals in OZR. Please see text for details.
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Figure 11 presents data describing microvessel and post-capillary venular density
within skeletal muscle of OZR and LZR. In both cases, microvascular and post-capillary
venular density were significantly reduced in OZR as compared to levels in age-matched
LZR.
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Figure 11. The change in skeletal muscle microvessel density in LZR and OZR. Results are presented following
tissue staining with Griffonia simplicifolia 1 lectin (GS-1 lectin; for general microvessel density) or dipeptidylpeptidase
IV (DPEP IV; for the post-capillary venular ends of capillaries). Data are presented as mean±SD, n=8 for both strains
of rats. * represents p<0.05 vs. LZR. Results represent n=8 observations from 8 animals in LZR; n=8 observations
from 8 animals in OZR. All tissues for these ex vivo experiments were taken from animals within Experimental
Groups 1 and 2. Please see text for details.

2.5

Discussion

To date, studies elucidating the impact of the metabolic syndrome on vascular regulation have
focused on arterial/arteriolar control. However, the arterial/arteriolar dysregulation observed
in the metabolic syndrome are (at least partially) a result of a pro-oxidant, pro-inflammatory
and pro-thrombotic environment, conditions which are known to also impact the
venular/venous side of the circulation. In an effort to provide a foundation from which more
targeted investigation can be directed, the present study investigated the impact of the
metabolic syndrome on skeletal muscle venular function at two levels (post-capillary and
collecting venules. Further, it was recently suggested that the pro-inflammatory and prooxidant conditions observed in post-capillary venules may be the initiating site for
microvascular rarefaction that is commonly associated with chronic metabolic disease
(Clough, 2015; Frisbee et al., 2014; Gilbert, 2013) and that fluid handling across the
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microcirculation may be altered by chronic impairments to glycemic control (Huxley and
Scallan, 2011; Scallan et al., 2015).
In the present study, impaired acetylcholine-induced venular dilation in OZR
appeared to be a result of elevated oxidative stress on venular nitric oxide bioavailability, as
treatment of the cremaster muscle with the antioxidant TEMPOL partially restored venular
function to that determined in LZR. While this is consistent with data determined in multiple
organs (Tune et al., 2017) and across arterial/arteriolar levels (Goodwill and Frisbee, 2012),
these data are critical for our understanding of both capillary handling of erythrocytes as well
as fluid exchange across the microcirculation. Interestingly, there appears to be a role for an
increased arachidonic acid-induced production of TxA2 in the loss of normal endotheliumdependent dilator reactivity, which is likely associated with the chronic pro-inflammatory
condition observed in OZR. While this increase in TxA2 can have multiple effects, including
impacting leukocyte adhesion (Morris et al., 2009; Tole et al., 2010; Totani et al., 2012) and
venular reactivity and responses, this also may represent a mechanism for modifying fluid
filtration/absorption across the capillary networks under settings of chronic metabolic disease
(Huxley and Scallan, 2011; Scallan et al., 2015) as well as contributing to the genesis of the
microvessel rarefaction discussed above (Frisbee et al., 2014).
Similar to arteries and arterioles, the sympathetic nervous system is a major
regulator of venous and venular tone, with sympathetic nerve fibers directly innervating α1
and α2 adrenoreceptors on vascular smooth muscle cells (Mellander and Lewis, 1963;
Tabrizchi and Pang, 1992; van Brummelen et al., 1986). However, in contrast to arterioles,
increased sympathetic nerve activity to small veins and venules results in a reduction in
vascular compliance, thus altering venous volume (capacitance) with comparatively less
impact on systemic resistance (Rothe, 1983). Although outside of the scope of the present
study, recent work has also demonstrated that a neuropeptide Y (NPY) -induced
constriction of veins in humans suggest that, in addition to α1- and α2-adrenoreceptor
mediated control, sympathetic activity can modify venous or venular tone through NPY
Y1 receptor activation (Luu et al., 1992; Pongor et al., 2010).
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The results from the present study suggest that venular reactivity to adrenergic stimuli
was elevated in OZR vs. LZR, with this effect being predominantly mediated via the 1
adrenoreceptor, but with an apparent role for the 2 adrenoreceptor as well in the larger
collecting venules. While there appeared to be a contribution to this effect mediated via the
impaired endothelial function, it was not clear that these contributions, whether mediated via
a loss of nitric oxide bioavailability or an increase in venular levels of TxA2 were significant
contributors to the altered tone regulation. However, it was clear this represented an alteration
to adrenergic signaling itself, and not a broad-spectrum shift in venular constrictor reactivity
at either the post-capillary or collecting venular level of the microcirculation.
The alterations to venular reactivity between LZR and OZR take on additional
significance when evaluated in response to metabolic challenge. Increasing metabolic
demand, instigated via electrical field stimulation of the cremaster muscle at increasing
frequency (McKay et al., 1998; Saito et al., 1994), resulted in a functional dilator and
hyperemic response in OZR that was restrained in comparison to that determined in LZR,
with the exception of the highest frequency of stimulation (3 Hz; where responses between
LZR and OZR venules were comparable).
Previous work by Hester’s group has implicated the venular release of prostacyclin
(PGI2), as a contributing mechanism to the dilation of the adjacent arterioles that perfuse the
capillary network under conditions of elevated metabolic demand in skeletal muscle (Hester
and Hammer, 2002; McKay et al., 1998; Saito et al., 1994). Further, it has also been
established that, under conditions of high oxidant stress and inflammation, the production of
PGI2 can be shifted to TxA2 (Zou. 2007), and that there is an increased arterial (Butcher et al.,
2013; Goodwill et al., 2008; Xiang et al., 2006) and venous (above) production of TxA2 in
OZR manifesting the metabolic syndrome. Speculatively, it may be that the negative impact
of vascular production of TxA2 on muscle perfusion that has been demonstrated previously
may partially be of venular origin, impacting not only its own reactivity, but also the caliber
of adjacent resistance arterioles leading into the microcirculation and contributing to the loss
in overall system flexibility and adaptive potential to imposed challenges (Frisbee et al., 2016;
Hester and Hammer, 2002). This speculation requires further investigation.
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As has been well established, the venular circulation is a low pressure “collecting
network” for the output of the high pressure “distribution network” of arteriolar perfusion
through the capillaries. While the increased adrenergic reactivity and impaired endothelial
function can serve to increase venular tone, the extent to which this shift in function acts to
increase perfusion resistance across the microcirculation is unclear at this time and will require
additional investigation. However, given the observation of an increased leukocyte adhesion
to the venular endothelium, this physical blockade has been previously demonstrated to
increase perfusion resistance within those regions (Harris et al., 1994; Harris and Skalak,
1993; Lipowsky et al., 1988) through the establishment of regions of “low radius” that are
no longer functionally able to effectively regulate diameter. From the perspective of mass
transport and exchange, the extent to which an increase in venular tone is sufficient to elevate
resistance downstream from the capillaries is unclear. From a network perspective, it is
reasonable to postulate that alterations in venular function may contribute to erythrocyte
distribution heterogeneity and lowered microvascular hematocrit previously reported in OZR
(Butcher et al., 2014).
An obvious implication for the increase in venular resistance would also be an increase
in the intravascular pressure within the venular environment, leading to an increased net fluid
filtration into the tissue across the microcirculation. Recent study by Scallan et al. (2015) may
provide insight into this outcome as the loss of nitric oxide bioavailability in the lymphatic
vessels of diabetic mice (where vascular nitric oxide levels have also been established to be
impaired) results in a release on the inhibition of phosphodiesterase 3 (PDE3), compromising
lymphatic integrity and increasing tissue edema. It will be intriguing to determine if this
fascinating observation on fluid handling across the microcirculation in diabetes represents
multiple contributing pathways involving impaired venular function as well.
In summary, with the development of the metabolic syndrome, venular function
within the skeletal muscle of OZR is impaired at both the post-capillary and collecting venular
segments. Along with an impaired endothelium dependent dilation, and a modest increase in
adrenergic constriction, the combination of a significant elevation in TxA2 production may
act to impair functional dilator and hyperemic responses at the venular level, and may
contribute to the impaired function at the adjacent arteriolar level as well (Hester and Hammer,
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2002). The implications of this shift in skeletal muscle venular function with the development
of the metabolic syndrome on issues such as aggregate microvascular perfusion resistance,
mass transport and exchange within with capillary networks, and fluid handling across the
microcirculation are compelling avenues for future interrogation.
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3.1 Abstract
Purpose: Although studies suggest elevated adrenergic activity paralleling metabolic
syndrome in obese Zucker rats (OZR), the moderate hypertension and modest impact on
organ perfusion questions the multi-scale validity of these data. Methods: To understand
how adrenergic function contributes to vascular reactivity in OZR, we utilized a multiscale approach to investigate pressure responses, skeletal muscle blood flow and vascular
reactivity following adrenergic challenge.

Results: For OZR, adrenergic challenge

resulted in increased pressor responses vs. lean Zucker rats (LZR); mediated via 1
receptors, with minimal contribution by either ROS or NO bioavailability.

In situ

gastrocnemius muscle of OZR exhibited blunted functional hyperemia, partially restored
with 1 inhibition, although improved muscle performance and VO2 required combined
treatment with TEMPOL. Within OZR in situ cremaster muscle, proximal arterioles
exhibited a more heterogeneous constriction to adrenergic challenge, biased toward
hyperresponsiveness, vs. LZR. This increasingly heterogeneous pattern was mirrored in
ex vivo arterioles, mediated via 1 receptors, with roles for ROS and NO bioavailability
evident in hyperresponsive vessels only. Conclusions: These results support the central
role of the 1 adrenoreceptor for augmented pressor responses and elevations in vascular
resistance but identify an increased heterogeneity of constrictor reactivity in OZR that is
presently of unclear purpose.
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List of Abbreviations
LZR: lean Zucker rat
OZR: obese Zucker rat
PRZ: prazosin
PHT: phentolamine
YOH: yohimbine
ROS: reactive oxygen species
NO: nitric oxide
PVD: peripheral vascular disease
TEMPOL: 4-hydroxy-2,2,6,6-tetramethylpiperidin-1 -oxyl
L-NAME: L-NG-Nitroarginine methyl ester
PSS: physiological salt solution
VO2: oxygen uptake
Q: muscle blood flow
CaO2: arterial oxygen content
CvO2: venous oxygen content
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3.2 Introduction
As has been well established, the development of peripheral vascular disease (PVD)
risk factors of sufficient severity can lead to profound alterations in the ability of resistance
vessels to regulate their degree of tone, and thus the levels of perfusion to and within the
tissues and organs they serve (17). Multiple previous studies across laboratories have
implicated alterations to vascular nitric oxide (NO) bioavailability and effectiveness (3),
altered arachidonic acid metabolism and the ensuing impacts on vascular tone (7, 15), the
impacts of reactive oxygen species (ROS; 13, 19), myogenic activation (16, 23, 28) and
alterations mediated via adrenergic signaling and vascular reactivity (1, 6, 21). However,
it is unclear that conclusions from previous studies on the impact of altered adrenergic
signaling/responses represent an accurate reflection of the true alterations to the integrated
system of microvascular perfusion and control within the setting of elevated PVD risk.
The metabolic syndrome is a multi-pathology state represented by the combined
presentation of multiple risk factors for PVD, including obesity, impaired glycemic control,
atherogenic dyslipidemia, and moderate hypertension; with the additional systemic
outcomes of a pro-oxidant, pro-inflammatory and pro-thrombotic state (4, 18). Arguably
the most important outcome of this condition is that it results in the impairment of perfusion
(both bulk perfusion and the spatial-temporal matching of perfusion with metabolic
demand) in the tissues and organs of the afflicted subject (8, 12). Previous studies have
provided compelling evidence that adrenergic traffic (5), adrenergic signaling (21) and
adrenergic vascular responses (9) may all be elevated within the metabolic syndrome (the
setting for elevated PVD risk). Further, it can clearly be demonstrated that treatment of
the moderate hypertension within metabolic syndrome in the obese Zucker rat (OZR)
model with prazosin (50 µg/kg) not only abolishes the elevated blood pressure that
develops within this state, it can equalize blood pressure characteristics to those determined
in the control strain, the lean Zucker rat (LZR, 27). However, what is unclear at this point
is how a general elevation in vascular adrenergic output with the potential for multiple
contributing elements, producing significant elevations in vascular resistance, functions
within the in vivo setting to produce the relatively mild/moderate elevations in arterial

62

pressure that have been determined (9, 29). Clearly, we have not arrived at an accurate
understanding of adrenergic control over muscle perfusion in the OZR model.
The purpose of the present study was to employ a multi-scale approach, integrating
in vivo, in situ, and ex vivo conditions to garner a more accurate understanding of the
changes in adrenergic control that are implicit for the development of skeletal muscle
microvasculopathy within the metabolic syndrome. In vivo approaches will incorporate
whole animal pressor responses with hindlimb blood flow measurements in anesthetized
animals, while in situ approaches will employ perfusion/muscle performance relationships
for gastrocnemius muscle and direct microscopic evaluation of vascular reactivity in
cremaster muscle, and ex vivo approaches will employ studies of isolated vascular
responses under specific challenged states. Taken together, these data will allow for a more
accurate understanding of adrenergic function in the control of muscle blood flow in OZR
will the full manifestation of the metabolic syndrome.

3.3 Materials and Methods
Animals: Male LZR (n=27) and OZR (n=45) were delivered at 6-7 weeks of age, and after
one week of acclimation to the local environment, were aged to ~17 weeks for final
experiment usage. All animals were used between 16 and 18 weeks of age. Animals were
fed standard chow and tap water ad libitum for all experiments unless otherwise noted.
Animals were housed in an accredited animal care facility, and all protocols received prior
IACUC approval from the West Virginia University. At ~17 weeks of age, each rat was
anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.), and all rats received
tracheal intubation to facilitate maintenance of a patent airway. In all rats a carotid artery and
an external jugular vein were cannulated for determination of arterial pressure and for
intravenous infusion of additional substances as necessary (e.g., anesthetic, heparin, etc.). In
addition, an aliquot of mixed venous blood was drawn from the jugular vein cannula for a full
profiling of metabolic and endocrine biomarkers (see below).
Experimental Series #1: In Vivo Whole Pressor Responses: Following the initial surgical
preparation (above), the femoral artery was isolated midway between the femoral triangle and
the knee and a perivascular blood flow probe was placed around the vessel (Transonic 0.7V)
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which was held in place via a micromanipulator. After a period of equilibration, each animal
was challenged with an intravenous infusion of the -adrenoreceptor agonist
norepinephrine (10 µg/kg), with pressor responses and hindlimb blood flow continuously
recorded. Subsequently, rats received a bolus intravenous infusion of the α1 adrenoreceptor
antagonist prazosin (1 mg/kg), the α2 adrenoreceptor antagonist yohimbine (5 mg/kg), or the
α1/α2 adrenoreceptor antagonist phentolamine (10 mg/kg), each followed by 30 minutes of
equilibration, in order to remove different components of adrenergic tone from the system
(n=5 for each antagonist; total n=15 for each strain). After a second norepinephrine challenge
with the respective antagonist present, animals were treated with bolus intravenous infusions
of TEMPOL (50 mg/kg) and a final subsequent treatment with L-NAME (100 mg/kg) to
assess the roles of reactive oxygen species and nitric oxide bioavailability in contributing to
responses following adrenergic challenge. After treatment with TEMPOL and again after the
treatment with L-NAME, a new challenge with norepinephrine was performed as described
above. Alterations in mean arterial pressure and femoral artery perfusion were monitored
following agonist infusion in order to determine peak responses and the restoration of baseline
(pre-treatment) conditions. All infused intravenous doses of drugs were corrected for
differences in circulating blood volume between LZR and OZR at this age (10, 24).
Experimental Series #2: In Situ Skeletal Muscle Perfusion: In a separate cohort of LZR
and OZR (n=5 for LZR; n=15 for OZR), the left gastrocnemius muscle was isolated in situ
as fully described previously (9). Subsequently, a perivascular flow probe (Transonic 0.5V
or 0.7V) was placed around the femoral artery, immediately proximal to its entry into the
muscle group, in order to measure blood flow to the gastrocnemius muscle. At the conclusion
of these procedures, an angiocatheter (24 gauge) was inserted into the femoral vein to allow
for sampling of venous blood from the contracting muscle to determine blood gas levels (done
using a Corning Rapid Lab Blood Gas Analyzer). The preparation was covered in PSSsoaked gauze and plastic film to minimize evaporative water loss and was placed under a heat
lamp to maintain temperature at 37C. At this time, heparin (500 IU/kg) was infused via the
jugular vein to prevent blood coagulation.
Upon completion of the surgical preparation, the gastrocnemius muscle was
stimulated to perform (via the sciatic nerve) bouts of isometric twitch contractions (4 Hz, 0.4
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ms duration, 5V) lasting for 3 minutes followed by 15 minutes of self-perfused recovery time,
with arterial pressure and femoral artery blood flow continuously monitored. Following the
initial contraction regimen under control conditions, rats were given an intravenous injection
of either prazosin (1 mg/kg; n=5), phentolamine (5 mg/kg; n=5) or yohimbine (5 mg/kg; n=5)
and the contraction regimen was repeated.

Each animal was treated with only one

adrenoreceptor antagonist. As above, following treatment of the animal with either
adrenoreceptor antagonist, animals were treated with TEMPOL and L-NAME as described
above and the contraction regimen was repeated with all data and blood collection also
repeated as described above.
Experiment Series #3: In Situ Skeletal Muscle Arterioles: In a dedicated cohort of rats
(n=7 for LZR; n=15 for OZR), the left cremaster muscle was prepared for television
microscopy (9). After completion of the preparation, the cremaster muscle was superfused
with PSS, equilibrated with a gas mixture containing 5% CO2 and 95% N2, and maintained at
35C as it flowed over the muscle. The ionic composition of the PSS was as follows (mM):
NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4 1.18, MgSO4 1.17, and NaHCO3 24.0. Arteriolar
diameter was determined with an on-screen video micrometer. After an initial post-surgical
equilibration period of 30 minutes, proximal (~75 µm diameter) and distal arterioles (~30 m
diameter) were selected for investigation in a clearly visible region of the muscle. Arterioles
chosen for study had walls that were clearly visible, a brisk flow velocity, and active tone, as
indicated by the occurrence of significant dilation in response to topical application of 10-5 M
adenosine. All arterioles that were studied were located in a region of the muscle that was
away from any incision.
Following an equilibration period, the responses of selected arterioles within the
cremaster muscle of LZR and OZR were assessed in response to increasing concentrations
of norepinephrine (10-10 – 10-5 M) or phentolamine (10-10 – 10-5 M), as described above, to
establish baseline reactivity to increasing adrenergic receptor activation and inhibition,
respectively.

As above, following washout, the cremaster muscle was treated with

TEMPOL by adding it to the superfusate (10-4 M), and the challenge with increasing
concentrations of norepinephrine and phentolamine was repeated. Finally, the TEMPOL-
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treated cremaster muscle was also treated with L-NAME (10-4 M; in the superfusate) and
challenge with the adrenergic agonist and antagonist was repeated.
Experiment Series #4: Ex Vivo Isolated Skeletal Muscle Resistance Arterioles: In
anesthetized rats, prior to the preparation of the cremaster muscle (above), the
intramuscular continuation of the right gracilis artery was identified, it’s in vivo diameter
determined using an eyepiece micrometer, and the vessel was surgically removed. In LZR,
arteriolar diameter estimated using this method was 1054 µm, while in OZR, the value
was reduced to 984 µm. Arterioles were placed in a heated chamber (37C) that allowed
the vessel lumen and exterior to be perfused and superfused, respectively, with
physiological salt solution (PSS; equilibrated with 21% O2, 5% CO2; 74% N2) from
separate reservoirs. Vessels were cannulated at both ends and were secured to inflow and
outflow pipettes connected to a reservoir perfusion system allowing intralumenal pressure
and lumenal gas concentration to be controlled. Vessel diameter was measured using
television microscopy and an on-screen video micrometer. Arterioles were extended to
their in situ length and were equilibrated at ~80% of the animal's mean arterial pressure
(~80 mmHg for LZR, ~100 mmHg for OZR). Active tone for vessels in the present study,
calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to
Ca2+-free PSS, and Dmax is the maximum diameter measured at the equilibration pressure
in Ca2+-free PSS, averaged 333% in LZR and 353% in OZR. To get a more accurate
presentation of the impact of altered adrenergic function on microvascular perfusion, we
elected to reduce the inclusion criteria for isolated arterioles in this study. Traditionally,
three criteria are employed to assess the viability of an individual vessel: 1) active tone
>25%, 2) robust constrictor response to challenge with phenylephrine, 3) viable endothelial
layer (dilator response to pharmacological challenge such as methacholine). However, as
one of the inclusion criteria represent the key outcome variable of the present study, this
has the potential to cause experimental bias in terms of which vessels get included into
experiments/analyses and which vessels are omitted for failing to achieve all three criteria.
For the purposes of the present study, we omitted criterion #2 and simply considered
vessels with sufficient active tone and viable endothelial function as having met the
inclusion requirements.

66

Prior to subsequent evaluation of arteriolar reactivity, the in vivo diameter of vessels
was restored through addition of low levels of norepinephrine to the vessel chamber. This
process required ~310-10 M norepinephrine in vessels from OZR. While vessels from
LZR usually regained their in vivo diameter without treatment with norepinephrine (n=12),
some vessels required a maximum norepinephrine concentration of ~110-10 M (n=3).
Following an equilibration period, arteriolar constriction was assessed in response to
increasing concentrations of phenylephrine (10-10 M – 10-5 M) or clonidine (10-10 M – 10-5
M) to establish baseline reactivity to α1- and α2-adrenoreceptor agonists, respectively.
Subsequently, reactivity of these isolated arterioles from LZR and OZR was assessed
following treatment of the vessel with TEMPOL (10-4 M), and following incubation with
L-NAME (10-4 M) to the TEMPOL-treated vessel.
Data and Statistical Analyses: In all cases, p<0.05 was taken to reflect statistical significance.
All data are presented as mean±SE.
In Vivo Pressor Response Experiments: All arterial pressure, hindlimb blood flow, and
calculated hindlimb vascular resistance (pressure/flow) data are presented as the change in the
parameter following treatment or challenge (Δ mmHg, Δ ml/g/min, Δ mmHg/(ml/g/min),
respectively).
Vascular Reactivity Experiments: Arteriolar constrictor responses following challenge with
adrenergic agonists or antagonists were fit with a three-parameter logistic equation:

 max − min 
y = min + 
log ED50 −x 
1 + 10

where y represents the change in arteriolar diameter, “min” and “max” represent the lower
and upper bounds, respectively, of the change in arteriolar diameter with increasing agonist
concentration, x is the logarithm of the agonist concentration and log ED50 represents the
logarithm of the agonist concentration ( x ) at which the response ( y ) is halfway between the
lower and upper bounds. Statistically significant differences in lower bound employed
ANOVA followed by Student-Newman-Keuls-test post-hoc as appropriate. Statistically
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significant differences in the distribution of adrenergic responses between LZR and OZR
utilized Student’s t-test for mean and variance.
For the purposes of categorizing arteriolar responses to adrenergic challenge into
“high’, “normal”, and “low” responders, the reactivity of all vessels (both OZR and LZR)
was compared to mean responses in LZR. Given the degree of heterogeneity in the
responses in OZR, a value of 20% was used as the threshold for inclusion into the “high”
or “low” responder categories.
In Situ Gastrocnemius Muscle Experiments: Muscle blood flow data were normalized to
gastrocnemius muscle mass, which did not differ between LZR (2.290.08 g) and OZR
(2.250.09 g). Muscle oxygen uptake (VO2) was calculated using the Fick equation:
𝑉𝑂2 = 𝑄 × (𝐶𝑎𝑂2 − 𝐶𝑣𝑂2 )
where Q represents blood flow, CaO2 represents arterial oxygen content and CvO2
represents venous oxygen content. Muscle fatigue curves were fit using a semi-logarithmic
relationship and the slope (β) coefficient was determined using curve fitting techniques.
Differences in muscle blood flow, O2 extraction, VO2 and the slope coefficient describing
muscle fatigue curves of contraction were determined using ANOVA, with StudentNewman-Keuls-test post-hoc as appropriate.
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3.4 Results
As summarized in Table 1, ~17 week old OZR demonstrated the full complement of
the metabolic syndrome. This included obesity, impaired glycemic control, dyslipidemia and
moderate hypertension. In addition, OZR also demonstrated a high level of chronic oxidant
stress and inflammation, with elevated levels of nitrotyrosine and TNF-, respectively.
Table 1. Baseline characteristics of 17-week-old LZR and OZR used in the present study. * p<0.05 versus LZR.

LZR

OZR

35811

67912*

MAP (mmHg)

98±4

129±6*

[Glucose]plasma (mg/dl)

105±9

164±11*

[Insulin]plasma (ng/ml)

1.4±0.2

7.6±1.0*

[Cholesterol]plasma (mg/dl)

84±7

132±11*

[Triglycerides]plasma (mg/dl)

91±10

361±20*

[Nitrotyrosine]plasma (ng/ml)

11±3

44±6*

Mass (g)

Table 2 presents the initial conditions for the vascular/systemic phenotypes across the
conditions of the present study. In these data, blockade of the 1 adrenergic system was
effective in blunting the development of hypertension in OZR, as well as many of the vascular
diameter and perfusion responses system. Further, the impact altering the vascular NO
bioavailability in OZR in terms of contributing to integrated vascular function was relatively
modest compared to the impact of alterations to adrenergic function.
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Table 2. Baseline hemodynamic characteristics of 17 week-old LZR and OZR used in the present study under control
conditions and in response to the different interventional treatments. AMP: mean arterial pressure (mmHg); QFEM: femoral
artery blood flow (ml/g/min); RFEM: resistance (mmHg/[ml/g/min]); (a-v)O2: oxygen extraction (ml/ml blood). * p<0.05 versus
LZR value.; † p<0.05 vs. strain control.

Figures 1 and 2 summarize data describing the pressor responses (Panels A), hindlimb
blood flow (Panels B) and perfusion resistance (Panels C) in OZR versus LZR under control
conditions and following treatment with phentolamine (Figure 1) and prazosin or yohimbine
(Figure 2). Any differences between LZR and OZR in terms of blood pressure and the
pressor response to intravenous infusion of norepineprhine itself were abolished by
treatment with either prazosin (the 1 blocker) or phentolamine (the 1/2 blocker), with
minimal impact of yohimbine (the 2 blocker). Treatment of OZR with TEMPOL (to blunt
ROS and increase NO bioavailability) or TEMPOL/L-NAME (to remove NO bioavailability
from a low ROS condition) had minimal impact on systemic responses to adrenergic
challenges.
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Figure 1. In vivo pressor responses (Panel A), in situ hindlimb blood flow (Panel B) and calculated vascular resistance across
the hindlimb (Panel C) for LZR and OZR following intravenous infusion of 10 mg/kg norepinephrine. Data are presented as
the change in the respective parameter from unstimulated, under control conditions and following pre-treatment with
phentolamine (PHT), phentolamine+TEMPOL (PHT-TEM) or phentolamine+L-NAME (PHT-LNM). * p<0.05 vs. LZR in
that condition; † p<0.05 vs. CON within that strain. Data are presented as mean±SE; n=5 for LZR; n=15 for OZR; please
see text for details.
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Figure 2. In vivo pressor responses (Panel A), in situ hindlimb blood flow (Panel B) and calculated vascular resistance across
the hindlimb (Panel C) for LZR and OZR following intravenous infusion of 10 mg/kg norepinephrine. Data are presented as
the change in the respective parameter from unstimulated, under control conditions and following pre-treatment with prazosin
(PRZ), prazosin+TEMPOL (PRZ-TEM), prazosin+L-NAME (PRZ-LNM), yohimbine (YOH), yohimbine+TEMPOL (YOHTEM) or yohimbine+L-NAME (YOH-LNM).. * p<0.05 vs. LZR in that condition; † p<0.05 vs. CON within that strain. Data
are presented as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details.

Data describing the fatigue curves (Panel A), active hyperemia (Panel B), oxygen
extraction (Panel C) and oxygen uptake (VO2; Panel D) for in situ gastrocnemius muscle of
LZR and OZR contracting at 4Hz (isometric twitch) under control conditions and following
treatment with phentolamine are presented in Figure 3. Following three minutes of imposed
elevations in metabolic demand, OZR demonstrated an increased development of muscle
fatigue, co-incident with a blunted hyperemic response. While O2 extraction was very similar
between the two strains, the combination of extraction and reduced blood flow resulted in a
significant reduction in VO2. Treatment of OZR with the combined 1/2 adrenoreceptor
antagonist phentolamine improved hyperemic responses when given alone, with additional
improvements to muscle performance and VO2 when followed up with antioxidant
(TEMPOL) treatment. Treatment of OZR with prazosin (Figure 4) mirrored the effect of
phentolamine, with an improved hyperemic responses when given alone and improved
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muscle performance and VO2 when given with the antioxidant. Any beneficial impacts of
TEMPOL in OZR were abolished by combined treatment with TEMPOL and L-NAME.
Treatment of OZR with the 2-adrenoreceptor antagonist yohimbine had no consistent or
significant effect from control values on muscle performance, hyperemic responses or blood
gas exchange measurements (Figure 5).

Figure 3. Data describing the performance (Panel A) and active hyperemic responses (Panel B) of in situ gastrocnemius
muscle of LZR and OZR contracting at 4Hz (isometric twitch). Also presented are O2 extraction (Panel C) and oxygen uptake
(VO2, Panel D) at three minutes of the contraction regimen. Data are presented under untreated control conditions and
following pre-treatment with phentolamine (PHT), phentolamine+TEMPOL (PHT-TEM) or phentolamine+L-NAME (PHTLNM). * p<0.05 vs. LZR; † p<0.05 vs. OZR; ‡ p<0.05 vs. OZR + PHT. Data are presented as mean±SE; n=5 for LZR; n=15
for OZR; please see text for details.
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Figure 4. Data describing the performance (Panel A) and active hyperemic responses (Panel B) of in situ gastrocnemius
muscle of LZR and OZR contracting at 4Hz (isometric twitch). Also presented are O2 extraction (Panel C) and oxygen uptake
(VO2, Panel D) at three minutes of the contraction regimen. Data are presented under untreated control conditions and
following pre-treatment with prazosin (PRZ), prazosin+TEMPOL (PRZ-TEM) or prazosin+L-NAME (PRZ-LNM). * p<0.05
vs. LZR in that condition; † p<0.05 vs. CON (100%) within that strain; ‡ p<0.05 vs. PRZ within that strain. Data are presented
as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details.
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Figure 5. Data describing the performance (Panel A) and active hyperemic responses (Panel B) of in situ gastrocnemius
muscle of LZR and OZR contracting at 4Hz (isometric twitch). Also presented are O2 extraction (Panel C) and oxygen uptake
(VO2, Panel D) at three minutes of the contraction regimen. Data are presented under untreated control conditions and
following pre-treatment with yohimbine (YOH), yohimbine+TEMPOL (YOH-TEM) or yohimbine+L-NAME (YOH-LNM).
* p<0.05 vs. LZR in that condition. Data are presented as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details.

Table 3 presents the baseline characteristics of in situ cremaster muscle proximal and
distal arterioles from LZR and OZR for the experiments described in Figures 6-9. Figures 6
and 7 summarize data describing the responses of in situ cremaster muscle arterioles located
proximally within the microvascular network to bi-directional manipulation of adrenergic
stimulation. In response to increasing adrenergic stimulation (increased norepinephrine)
proximal arterioles from both LZR and OZR exhibited robust constrictor responses (Figure
6). However, while arterioles from LZR exhibited a relatively consistent response, with 38/50
vessels constricting by at least 60% of their resting diameter with 10-6 M norepinephrine, there
was a significant shift in the distribution of reactivity with the development of the metabolic
syndrome in OZR as only 19/50 vessels demonstrated a comparable response, while 21/50
vessels exhibited a stronger degree of reactivity, with a significantly reduced ED50 value,
essentially closing off fully at lower concentrations of stimulation, and 10/50 vessels exhibited
a significant reduction to constrictor responses, with an elevated ED50. In both LZR and OZR,
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treatment with either TEMPOL or L-NAME had minimal consistent impacts on adrenergic
responses in either strain.
Table 3. Baseline vascular characteristics of 17 week-old LZR and OZR used in the present study under control
conditions and in response to the different interventions. Data are presented for in situ cremaster muscle proximal
(CPA) and distal arterioles (CDA) as well as ex vivo gracilis muscle resistance arterioles (GA). ID: internal diameter
(resting; m); MaxD: maximum diameter (m) under 10-3M adenosine + 10-3M sodium nitroprusside (in situ) or Ca2+free conditions (ex vivo); AT: calculated active tone (%; please see text for detail). Despite multiple trends, no
significant differences in the results below were determined.

Figure 6. Constrictor responses from in situ cremaster muscle proximal arterioles from LZR (Panel A) and OZR (Panel D)
in response to increasing concentrations of norepinephrine. In Panels A and D, different levels of reactivity are colored such
that “high” responders are red, “low” responders are green and “normal” responders are blue. These colors are “greyed” in
subsequent panels to facilitate comparisons. Panels B and E present the impact of TEMPOL on arteriolar constrictor responses
in LZR and OZR, respectively. Panels C and F present the impact of L-NAME on arteriolar constrictor responses in LZR
and OZR, respectively. * p<0.05 vs. “normal” in that strain; † p<0.05 vs. responses in untreated arterioles within that strain
and reactivity category. Data are presented as mean±SE; n=7 for LZR; n=15 for OZR; please see text for details.
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With increasing phentolamine treatment (Figure 7), used to simulate progressive
removal of adrenergic tone to proximal arterioles of LZR and OZR, “normal” responders in
both strains exhibited comparable dilation. However, arterioles in both strains that were
identified as being “high” responders exhibited a very limited dilator response with increasing
phentolamine concentration, while arterioles that were “low” responders to norepinephrine
challenge demonstrated the greatest dilation in response to increasing concentration of
phentolamine. In both strains, neither TEMPOL nor L-NAME treatment had a consistent and
significant impact on the phentolamine-induced dilation in “normal” and “high” responders.
However, in “low” responders of either strain, treatment of arterioles with L-NAME blunted
dilator responses to phentolamine.

Figure 7. Dilator responses from in situ cremaster muscle proximal arterioles from LZR (Panel A) and OZR (Panel D) in
response to increasing concentrations of phentolamine. In Panels A and D, different levels of reactivity are colored such that
“high” responders are red, “low” responders are green and “normal” responders are blue (classification of responders was
performed for Figure 8). These colors are “greyed” in subsequent panels to facilitate comparisons. Panels B and E present
the impact of TEMPOL on arteriolar dilator responses in LZR and OZR, respectively. Panels C and F present the impact of
L-NAME on arteriolar dilator responses in LZR and OZR, respectively. * p<0.05 vs. “normal” in that strain; † p<0.05 vs.
responses in untreated arterioles within that strain and reactivity category. Data are presented as mean±SE; n=7 for LZR;
n=15 for OZR; please see text for details.

Using the data presented above, Figure 8 presents the relationship between in situ
proximal arteriolar constrictor responses to 10-8 M norepinephrine and the number of
occurrences (out of a total n=50 for each strain). These data clearly illustrate the changing
distribution in constrictor responses to adrenergic challenge, where LZR exhibit a tighter
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distribution of responses with lower variability than OZR, where proximal arteriolar responses
to adrenergic challenge are more distributed, with a greater occurrence of constrictor
responses at the “tails” of the distribution. Statistical analysis of the mean and variance
between LZR and OZR demonstrated that the distributions of adrenergic responses where
significantly different between the two strains.
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Mean: 30.4
Variance: 65.1
Skewness: 0.008
Kurtosis: 0.06
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Figure 8. Distribution of constrictor responses of in situ cremaster muscle proximal arterioles to 10-8 M norepinephrine. Data
are presented as the frequency of occurrence for a level of constrictor response (out of 50 occurrences) for arterioles from LZR
and OZR; demonstrating the widening and flattening of the distribution in OZR as compared to that for LZR. The distribution
for LZR passes the normality test (p=0.834), while that for OZR does not (p=0.025). As such, while the distributions for LZR
and OZR are considered to be significantly different (p=0.026), they cannot both be classified as normal distributions.

Figure 9 presents the responses of distal in situ cremaster muscle arterioles of LZR
and OZR to increasing concentrations of norepinephrine (Panels A and B) and phentolamine
(Panels C and D), respectively. Under neither control conditions, nor pre-treatment conditions
(TEMPOL or L-NAME) were responses of in situ distal arterioles significantly different
between strains, nor was any evidence for an altered distribution of reactivity present (Panel
E).
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Figure 9. Mechanical responses from in situ cremaster muscle distal arterioles from LZR (Panel A) and OZR (Panel B) in
response to increasing concentrations of norepinephrine (Panels A and B, respectively) or phentolamine (Panels C and D,
respectively). Data are presented under untreated control conditions and following pre-treatment of the cremaster muscle with
TEMPOL or L-NAME. Also presented is the distribution of constrictor responses of in situ cremaster muscle proximal
arterioles to 10-8 M norepinephrine (Panel E). Data are presented as the frequency of occurrence for a level of constrictor
response (out of 50 occurrences) for arterioles from LZR and OZR; demonstrating the lack of a difference between the
distribution for LZR and OZR (p=0.909). Data are presented as mean±SE; n=7 for LZR; n=15 for OZR; please see text for
details. Please see text for details.
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Figure 10 presents the reactivity of ex vivo gracilis muscle first order resistance
arterioles of LZR and OZR to increasing concentrations of the 1 adrenoreceptor agonist
phenylephrine (for data describing the baseline characteristics of ex vivo arterioles, please see
Table 3). When the inclusion criteria of “sufficient adrenergic reactivity” was eliminated
(please see above), a similar widening of constrictor responses to adrenergic challenge was
determined in OZR as compared to LZR (Panel A). In “high” responders, the increased
constrictor reactivity was significantly attenuated following treatment of the vessel with
TEMPOL, while treatment with L-NAME was without effect (Panel B). This effect was less
evident in “normal” (Panel C) and “low” (Panel D) responding arterioles from OZR, such that
treatment with either TEMPOL or L-NAME resulted in minimal impact to phenylephrineinduced reactivity. Constrictor responses to increasing concentrations of the 2
adrenoreceptor agonist clonidine did not exhibit a difference between LZR and OZR (Panel
E), and this was not significantly impacted by treatment with TEMPOL or L-NAME.
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Figure 10. Constrictor responses from ex vivo gracilis muscle resistance arterioles from LZR and OZR in response to
increasing concentrations of phenylephrine (α1 agonist; Panels A-D) or clonidine (α2 agonist; Panel E). Data for
phenylephrine-induced constriction under control conditions are presented in Panel A, which also demonstrate the different
classes of reactivity. These data are “greyed” in subsequent panels such that the impact of pre-treatment with TEMPOL, LNAME or both are presented for vessels in the “high” (Panel B), “normal” (Panel C) and “low” responder (Panel D) categories.
* p<0.05 vs. “normal” in that strain; † p<0.05 vs. responses in untreated arterioles within that strain and reactivity category.
Data are presented as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details.
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3.5 Discussion
The underlying logic of the present study stemmed from a lack of clarity between the
results of previous studies suggesting an increase in sympathetic activity (5), adrenergic
constrictor reactivity (9, 11) and an increase in some elements of adrenergic intracellular
signaling (21) in metabolic syndrome, despite the consistent observation that the development
of both hypertension and any elevations in vascular resistance of adrenergic origin were
relatively modest (4, 12, 16, 29). This suggests that a potential disconnect may exist between
the interpretations from data collected at higher resolutions (e.g., in situ vascular networks, ex
vivo resistance vessels), and responses determined under in vivo conditions. The present study
was designed to address this discrepancy by identifying the source for this lack of clarity.
At the lowest level of spatial resolution, the in vivo preparation, OZR clearly exhibited
an increased pressor response following adrenergic challenge as compared to responses
determined in LZR, while use of adrenoreceptor antagonists demonstrated that this increased
response was largely mediated via the 1 receptors. While consistent with previous evidence
(9, 11), results from the present study also provide insight into the role of vascular oxidant
stress/nitric oxide bioavailability balance on the pressor response to adrenoreceptor
stimulation. Despite the clearly established presence of elevated vascular oxidant stress in
OZR, the current results suggest that the reduction in vascular ROS levels following
TEMPOL treatment was without significant impact on the magnitude of the pressor response
in OZR, nor did the subsequent L-NAME–based abolition of rescued nitric oxide
bioavailability consistently impact the magnitude of the pressor responses between groups.
Given the well-established relationships in question and the effectiveness of the treatment
interventions in impacting ROS and NO levels, the most reasonable interpretation of these
data is that, in comparison to the 1-mediated responses, a manipulation of vascular nitric
oxide bioavailability was of insufficient significance to impact pressor responses at this level
of resolution.
When taking these observations to the next higher level of resolution, the in situ
skeletal muscle, a roughly comparable condition was evident to that for the in vivo setting.
Specifically, the accelerated rate of muscle fatigue and blunted active hyperemia with 4Hz
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twitch contraction in OZR vs. LZR were improved following 1 receptor blockade (but only
with concurrent antioxidant treatment); with no significant effect associated with 2 receptor
antagonism under any condition. This enhanced function was associated with the greatest
improvements to VO2 which also suggests that the combination of adrenoreceptor antagonism
and antioxidant therapy results in an overall improvement to the perfusion-based elements of
mass transport and exchange beyond that for 1 adrenoreceptor antagonism alone. Further,
the importance of “rescued” vascular nitric oxide bioavailability on contributing to skeletal
muscle blood flow, especially during periods of elevated metabolic demand, was
demonstrated following the application of L-NAME under TEMPOL-treated conditions.
These results also provide support for previous observations indicating that general
blunting of adrenergic constriction can improve hyperemic responses in skeletal muscle in
metabolic syndrome (8, 9, 11, 21), but are of limited effectiveness in terms of improving
muscle performance unless treatments are combined with antioxidant agents to directly
improve endothelial function (8). As antioxidant treatment alone was without impact on either
bulk flow responses or muscle performance in the absence of 1 adrenoreceptor inhibition,
these observations suggest that a conceptual division may be appropriate for the impact of the
metabolic syndrome muscle performance outcomes. It may be that the modest reduction in
skeletal muscle blood flow in OZR primarily reflects adrenergic constraint sufficient to hinder
metabolic sympatholysis, while endothelial dysfunction (although ubiquitously present) is
more important for the higher resolution matching of perfusion distribution to metabolic need
within tissue.
Previous studies have suggested that there is a general increase in sympathetic traffic,
intracellular signaling, and/or vascular constrictor responses to adrenergic challenge with the
development of metabolic syndrome (5, 9, 21). However, as stated above, in vivo data do not
strongly support this contention. Results from the in situ cremaster muscle of OZR as
compared to responses in LZR may provide insight into this discrepancy, as constrictor
responses of proximal resistance arterioles to increasing adrenergic stimulation exhibited a
much more consistent response in LZR than in OZR, with a narrower distribution. In contrast,
the responses to adrenergic challenge in OZR exhibited a larger spread in their magnitude
with a greater proportion of vessels demonstrating both increased and decreased
83

responsiveness (although more commonly toward increased reactivity). Similarly, when
treated with increasing concentrations of the 1/2 adreneroreceptor antagonist phentolamine,
arterioles that were classified as “high responders” exhibited the lowest degree of dilation,
while the reverse was true for vessels that were “low responders”. Obviously, this somewhat
skewed, but broader distribution of adrenergic constrictor responses, may contribute to the in
vivo outcomes that have been identified in OZR, and may explain why they are more modest
than would otherwise be predicted.
Based on the current data, some of this heterogeneity in reactivity may reflect
variability in the initial conditions. Arterioles with increased tone under resting conditions
will be unable to exhibit the full range of constriction in response to any stimulus as compared
to levels from those of a greater initial diameter/reduced level of tone. Conversely, those with
less tone (greater diameter) at rest have less ability to respond to the removal of adrenergic
constriction as compared to those with a greater degree of tone. Given this, the greater
heterogeneity of reactivity in the microcirculation of OZR vs. LZR may reflect the concept of
the “optimal diameter” or “optimal wall tension” as originally described by Gore (14). In that
work, the author determined that the greatest degree of reactivity was realized when vessels
had the ability to constrict or dilate through a set range of optimal responsiveness and that
moving the initial condition away from this range in either direction was associated with a
severe decline in stimulus-induced reactivity. It may be that the more heterogeneous
reactivity of proximal resistance arterioles from OZR in response to adrenergic challenge
could partially reflect a loss of coordination through the sympathetic nerves that results in an
increasingly heterogeneous initial “resting” condition which impacts adrenergic control over
resistance at both the individual vessel and network levels.

Recent work by Rachev and

colleagues (22) has shed further light on this concept and provided compelling evidence of an
optimal state of vascular mechanics that may result in the most efficient adaptability to
changing conditions.
Interestingly, the increased variability in resistance arteriolar adrenergic reactivity in
OZR following development of the metabolic syndrome in proximal arterioles, was not
evident in distal arterioles. Using intravital microscopy, our group has shown that adrenergic
vasoconstriction, in the rat gluteus maximus microcirculation, displays spatial-dependency.
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In this work, we reported that the greatest 1R and 2R effects were noted in lower order
(proximal) arterioles (i.e., 1A and 2A); whereas, sympathetically-mediated peptidergic and
purinergic control dominated in higher order distal and terminal arterioles (2). Such spatial
heterogeneity in sympathetic control provides a plausible explanation for the lack of
adrenergic influences measured in distal microcirculation of OZR. Thus, future work
addressing the contributions of NPY and ATP to microvascular regulation/dysregulation in
the metabolic syndrome will likely reveal new mechanisms of sympathetic dysregulation in
the distal microcirculation.
An important component of the present study was the removal of “robust adrenergic
reactivity” as an inclusion criterion for the study of ex vivo resistance arterioles. When this
was incorporated, a comparable pattern of divergence in adrenergic constrictor reactivity is
present in the larger resistance arterioles of OZR vs. LZR to that for the proximal arterioles
within the cremaster muscle. The increased variability in the adrenergic constrictor reactivity
of ex vivo arterioles of OZR appears to reflect intrinsic vascular, and perhaps endothelial cell,
function itself, as treatment of “high responders” with TEMPOL blunted the adrenergic
responses, which was subsequently abolished following additional treatment with L-NAME.
These effects were not observed in “normal” or “low” responders where the ability of
TEMPOL and/or L-NAME to impact adrenergic constriction was severely attenuated. As a
result of a relaxed inclusion criteria, the magnitude of the net increase in adrenergic
constriction in large resistance arterioles of OZR was elevated as compared to LZR, but to a
far less extent than previously estimated.
The results of the present study are important for several reasons. Foremost, these
data provide evidence for the role of altered adrenoreceptor reactivity in the metabolic
syndrome on integrated vascular function from a multi-scale perspective. Clearly, the
increased pressor response to adrenergic challenge largely reflects activity mediated through
the 1 receptor and does not appear to be substantially impacted by treatment against elevated
oxidant stress or a potential loss in vascular nitric oxide bioavailability. While responses from
the hindlimb preparation suggested that hyperemic responses of OZR skeletal muscle can be
improved by 1 adrenoreceptor inhibition, additional antioxidant treatment of OZR was
required to improve muscle performance, suggesting divergent roles for adrenergic constraint
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on bulk flow and endothelial function for higher resolution perfusion:demand matching.
Finally, results at the highest levels of spatial resolution, the in situ cremaster muscle and ex
vivo microvessel revealed an increased diversity of vascular reactivity in OZR following
adrenergic challenge. The immediate question from these results is why an increased diversity
of adrenergic constrictor reactivity develops in OZR with progression of metabolic syndrome.
There does not appear to be evidence that a compensatory change in constrictor
reactivity for the shifts in adrenergic responses develops in OZR, as there is no evidence that
changes in myogenic activation between strains or within an individual animal that would
match with increased adrenergic reactivity heterogeneity exists (i.e., vessels with low
adrenergic reactivity having elevated myogenic responses, etc.). Additionally, there is no
prior evidence to which the authors are aware that constrictor responses to other agents (e.g.,
endothelin, angiotensin II, serotonin) are significantly altered in OZR (27). However, there
is evidence from some investigators that pressor reflexes may be blunted in OZR, although
the mechanism underlying this and its generalizability for the model remain unclear (25). As
such, one is left with speculation. Do vessels with “low” adrenergic constriction help the
networks maintain an appropriate active hyperemic response, or at least largely maintain it?
In an animal model that has been established as suffering from a profound loss of the
microvascular network flexibility necessary to respond to imposed stressors (8), does the
increased heterogeneity of adrenergic responses help to maintain system flexibility?
Perhaps even more importantly for clinical/population health outcomes, alterations in
adrenergic tone and function have been previously implicated as contributing to the regulation
of microvessel density, and chronic 1 adrenoreceptor inhibition with prazosin is an
established systemic model of angiogenesis (30). Of greatest relevance to the present study,
may be recent work from the Haas group, where chronic prazosin treatment blunted the
development of microvessel rarefaction in chronic corticosterone-treated rats (20). Given the
presence of high cortisol/corticosterone levels in OZR, it may be that tissue regions containing
resistance arterioles with elevated adrenergic reactivity may be associated with earlier or more
severe levels of microvascular rarefaction (12). At this point, answers to the above questions
are unknown. However, the challenge that the metabolic syndrome and PVD risk pose for
public health outcomes (26), combined with the clear potential for improving microvascular
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network function and perfusion with appropriate intervention, make this a compelling avenue
for future investigation.
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4.1 Abstract
It has been long known that chronic metabolic disease is associated with a parallel increase
in the risk for developing peripheral vascular disease. Although more clinically relevant,
our understanding about reversing established vasculopathy is limited in comparison to our
understanding of the mechanisms and development of impaired vascular structure/function
under these conditions. Using the 13-week old obese Zucker rat (OZR) model of the
metabolic syndrome, where microvascular dysfunction is sufficiently established to
contribute to impaired skeletal muscle function, we imposed a 7-week intervention of
chronic atorvastatin (ATOR) treatment, chronic treadmill exercise (EXER), or both. By
20 weeks of age, untreated OZR manifested a diverse vasculopathy that was a central
contributor to poor muscle performance, perfusion and impaired O2 exchange. ATOR or
EXER, with the combination being most effective, improved skeletal muscle vascular
metabolite profiles (i.e., nitric oxide, PGI2 and TxA2 bioavailability), reactivity and
perfusion distribution at both individual bifurcations and within the entire microvascular
network versus responses in untreated OZR. However, improvements to microvascular
structure (i.e., wall mechanics and microvascular density) were less robust.

The

combination of the above improvements to vascular function with interventions resulted in
an improved muscle performance and O2 transport and exchange versus untreated OZR,
especially at moderate metabolic rates (3Hz twitch contraction). These results suggest that
specific interventions can improve specific indices of function from established
vasculopathy, but this process was either incomplete after 7 weeks duration or that
measures of vascular structure are either resistant to reversal or require better targeted
interventions.

Key Words: vascular dysfunction, rodent models of the metabolic syndrome, regulation of
blood flow, peripheral vascular disease, microvascular dysfunction, reversing vascular
disease
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New and Noteworthy
We used atorvastatin and/or chronic exercise to reverse established microvasculopathy in
skeletal muscle of rats with metabolic syndrome.

With established vasculopathy,

atorvastatin or exercise had moderate abilities to reverse dysfunction, combined
application of both was more effective at restoring function. However, increased vascular
wall stiffness and reduced microvessel density were more resistant to reversal.
List of Abbreviations
ANOVA: analysis of variance
AT: active tone
ATOR: atorvastatin
CaO2: arterial oxygen content
CvO2: venous oxygen content
EIA: enzyme immune assay
EXER: exercise
GS-1: Griffonia simplicifolia-1 lectin
ID: internal diameter
IL-10: interleukin 10
IL-1: interleukin 1 beta
IL-6: interleukin 6
L-NAME: L-NG-Nitroarginine methyl ester
LZR: lean Zucker rat
MAP: mean arterial pressure
MCP-1: monocyte chemoattractant protein-1
MTT: maximal twitch tension
MVD: microvessel density
NO: nitric oxide
OZR: obese Zucker rat
PSS: physiological salt solution
PVD: peripheral vascular disease
Q: muscle blood flow
ROS: reactive oxygen species
TEMPOL: 4-hydroxy-2,2,6,6-tetramethylpiperidin-1 -oxyl
TNF-α: tumor necrosis factor-alpha
TxA2: thromboxane A2
VO2: oxygen uptake
WT: wall thickness
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4.2 Introduction
One of the major contributors to the functional or clinical manifestations of
peripheral vascular disease is the progressive loss of microvessel and microvascular
network structure and function which is tightly coupled to developing metabolic disease in
afflicted animals (9, 15) or humans (20, 25). This compromised function within the
microcirculation can take multiple forms, including impairments to arteriolar reactivity,
mechanical changes to the microvessel wall, and a progressive lowering of microvessel
density (rarefaction) within the skeletal muscle (14, 26). Taken together, these impede
effective mass transport and exchange, and the regulation of blood flow to, and perfusion
within, skeletal muscle (9, 23).

In addition, while the functional impact of these

impairments may be modest under resting or low-metabolic demand conditions, their
cumulative impact becomes more severe as muscle activity increases (6, 13, 28). Given
the insidious nature of the development of peripheral vascular diseases (PVD), and the very
real clinical challenge of reversing the development of established vasculopathy in affected
patients (rather than blunting its subsequent development from an otherwise “healthy”
condition), investigation into if/how a compromised microvascular network can be restored
to a more normal level of structure and integrated function represents an important area of
investigation.

Arterial reconstructive surgery for symptomatic PVD can restore

macrovascular perfusion but its effects on microvascular dysfunction are unclear.
Persistent microvascular dysfunction following successful macrovascular reperfusion may
explain why arterial reconstruction does not always lead to wound healing or amelioration
of symptoms in patients with PVD (12)
Previous studies in our laboratory (13, 14) and from others (9, 31-34) have clearly
established that the loss of normal microvascular structure and function parallels the
development of metabolic disease. Of particular relevance to the present study, we have
recently demonstrated that rarefaction in the skeletal muscle of the obese Zucker rat (OZR)
appears to develop in stages, where an early reduction of microvessel density is well
predicted by an oxidant stress- and inflammation-dependent shift in arachidonic acid
metabolism toward increasing levels of thromboxane A2 (TxA2), with a later stage of
rarefaction that is associated with a loss in vascular nitric oxide bioavailability (14).
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However, any interventions that have been employed to improve these vascular outcomes
have been relevant for blunting the severity of the vasculopathy that ultimately develops,
rather than reversing an established compromised condition once it has already developed
(16, 18).
The OZR (fa/fa) represents a model of the metabolic syndrome that is
fundamentally grounded in a mutation in the leptin receptor leading to severe leptin
resistance, chronic hyperphagia and the ensuing development of severe obesity (2, 11).
Tracking with the severe obesity is a steadily worsening glycemic control, a progressive
dyslipidemia and a moderate hypertension, with the additional co-morbidities of a growing
pro-oxidant, pro-inflammation, and pro-thrombotic state (22).

OZR exhibit high

translational relevance to the metabolic syndrome condition in humans (29) and manifest
a progressively worsening skeletal muscle microvascular structure and function that
parallels that determined in affected humans.
The purpose of the present study was to utilize two clinically-relevant interventions
against the further development of established PVD – increased physical activity/exercise
and chronic ingestion of the HMG CoA-reductase inhibitor atorvastatin – to determine if
an established impairment to skeletal muscle arteriolar and microvascular structure and
function can be reversed toward normal prior to reaching its maximum severity. For this
study, “reversibility” is defined as the effectiveness of the imposed intervention in OZR to
restore the normal level of measured parameter (e.g., nitric oxide bioavailability) to that
determined in untreated LZR. This study tested the hypothesis that, once developed,
skeletal muscle microvascular impairments in the OZR model of the metabolic syndrome
cannot be reversed, as the environment within the microvasculature cannot be modified
sufficiently to generate a condition that allows for reversibility. We propose that a deeper
understanding of the reversibility of skeletal muscle microvasculopathy that occurs in
metabolic disease will provide greater insight into the clinical challenge of most direct
relevance to human subjects.
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4.3 Materials and Methods
Animals: Male lean (LZR) and OZR (Harlan) were fed standard chow and drinking water ad
libitum, unless otherwise indicated, were housed in an accredited animal care facility at either
the West Virginia University Health Sciences Center (all experimental procedures) or at the
University of Western Ontario (ex vivo vascular experiments only) and all protocols received
prior IACUC approval. Animals were used for terminal experiments at 13 (initial condition)
or 20 (following intervention) weeks of age. At 13 weeks of age, LZR and OZR (n=6 for
each) were either used for terminal experiments (to establish the initial condition within the
microcirculation) or were placed into one of four groups:
1. Time control (n=6; rats were housed without intervention and aged to ~20 weeks)
2. Atorvastatin (n=6; 25 mg•kg-1•day-1; mixed with food; Ref.18)
3. Treadmill exercise (n=6; 20 m/min, 5% incline, 60 minutes/day, 6 days/week; Ref.
16)
4. A combination of atorvastatin treatment and treadmill exercise as described above, to
~20 weeks of age; n=6.
At the time of final usage, after an overnight fast, rats were anesthetized with injections of
sodium pentobarbital (50 mg/kg, i.p.), and received tracheal intubation to facilitate
maintenance of a patent airway. In all rats, a carotid artery and an external jugular vein were
cannulated for determination of arterial pressure and for infusion of supplemental anesthetic
or pharmacological agents, as necessary. Blood samples were drawn from the venous cannula
within approximately 20 minutes following implantation for determination of insulin
concentrations (Cayman Chemical Company, Ann Arbor, MI), plasma nitrotyrosine levels
and markers of inflammation using commercially available EIA systems (Luminex 100 PS;
EMD Millipore, Billerica, MA). While glucose levels were determined at the time of the
blood draw (Freestyle, Abbott Diabetes Care, Inc, Alameda, CA), all other samples were spun
to remove the plasma, which was snap frozen in liquid N2 until they could be analyzed as
groups.
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized rats, prior
to the preparation of the cremaster muscle (below), the intramuscular continuation of the
right gracilis artery was identified, the in vivo length and diameter estimated using an
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eyepiece micrometer, and the vessel was surgically removed and doubly-cannulated (7).
Within each arteriole, vessel reactivity was evaluated in response to application of
acetylcholine (10-9 M – 10-6 M) or hypoxia (reduction in PO2 from ~135 mmHg to ~50
mmHg).

Subsequently, vessels were treated with TEMPOL (10-4 M) to assess the

contribution of vascular oxidant stress to these mechanical responses.
At the conclusion of all procedures described above, vessel diameter was
determined under Ca2+-free conditions over a range of intraluminal pressures spanning 0
mmHg to 160 mmHg (in 20 mmHg increments) for the subsequent calculation of wall
mechanics. For these procedures, 5 mmHg was used as the “zero pressure” condition to
prevent vessel collapse and to eliminate the potential for creating a vacuum within the
vessel.
Preparation of In Situ Cremaster Muscle: In each rat, the left cremaster muscle was
prepared for television microscopy (24). After completion of the preparation, the muscle was
superfused with PSS, equilibrated with a gas mixture containing 5% CO2 and 95% N2, and
maintained at 35C as it flowed over the muscle at a rate of 2.5 – 3.0 ml/min. The ionic
composition of the PSS was as follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4
1.18, MgSO4 1.17, NaHCO3 24.0, and disodium EDTA 0.03. After an initial post-surgical
equilibration period of 30 minutes, two sets of arterioles and their bifurcations were selected.
Proximal (~75 m diameter) and distal (~40 m) parent arterioles and their immediate
daughter branches were selected for investigation in a clearly visible region of the muscle
(please see reference 17 for a full description). All arterioles chosen for study had walls that
were clearly visible, a brisk flow velocity, and active tone, as indicated by the occurrence of
significant dilation in response to topical application of 10-5 M adenosine. All arterioles that
were studied were located in a region of the muscle that was away from any incision.
Initial evaluations of in situ arteriolar reactivity were assessed by determining mechanical
responses (using on-screen videomicroscopy) to increasing concentrations of acetylcholine
(10-9-10-6 M) and norepinephrine (10-10-10-7 M). Subsequently, the diameter and perfusion
(using optical Doppler velocimetry) responses of both the ‘parent’ and ‘daughter’ arterioles
at either level of the microcirculation were assessed under resting conditions within the
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cremaster muscle of each rat. All procedures were then repeated following treatment of
the in situ cremaster muscle with the anti-oxidant TEMPOL (10-3 M; within the
superfusate; for a minimum of 40 minutes prior to any subsequent data collection).
Measurement of Vascular NO Bioavailability: From each rat, the abdominal aorta was
removed and vascular NO production was assessed using amperometric sensors (World
Precision Instruments, Sarasota, FL).

Briefly, aortae were isolated, sectioned

longitudinally, pinned in a silastic coated dish and superfused with warmed (37C) PSS
equilibrated with 95% O2 and 5% CO2. An NO sensor (ISO-NOPF 100) was placed in
close apposition to the endothelial surface and a baseline level of current was obtained.
Subsequently, increasing concentrations of methacholine (10-10–10-6 M) were added to the
bath and the changes in current were determined. To verify that responses represented NO
release, these procedures were repeated following pre-treatment of the aortic strip with LNAME (10-4 M).
Determination of Vascular Metabolites of Arachidonic Acid: Vascular production of 6keto-prostaglandin F1 (6-keto-PGF1; the stable breakdown product of PGI2; Ref. 27), and
11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma breakdown product of
TxA2; Ref. 8) was assessed in response to challenge with reduced PO2 using pooled arteries
(femoral, saphenous, iliac) from LZR and OZR. Pooled arteries from each animal were
incubated in microcentrifuge tubes in 1 ml of PSS for 30 minutes under control conditions
(21% O2). After this time, the superfusate was removed, stored in a new microcentrifuge tube
and frozen in liquid N2, while a new aliquot of PSS was added to the vessels and the
equilibration gas was switched to 0% O2 for the subsequent 30 minutes. After the second 30minute period, this new PSS was transferred to a fresh tube, frozen in liquid N2 and stored at
-80C. Metabolite release by the vessels was determined using commercially available EIA
kits for 6-keto-PGF1 and 11-dehydro-TxB2 (Cayman).
Histological Determination of Microvessel Density: From each rat, the gastrocnemius
muscle from the left leg was removed, rinsed in PSS and fixed in 0.25% formalin. Muscles
were embedded in paraffin and cut into 5 m cross sections. Sections were incubated with
Griffonia simplicifolia I lectin (GS-1) for subsequent determination of microvessel density.
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GS-1 is a general stain that labels all microvessels <20 m in diameter (19). Gastrocnemius
muscle microvessel density was determined using fluorescence microscopy) as described
previously (14).
Preparation of In Situ Blood Perfused Gastrocnemius: In a separate set of age-matched
LZR and OZR under the conditions outlined above, the left gastrocnemius of each animal
was isolated in situ (13). Heparin (500 IU/kg) was infused via the jugular vein to prevent
blood coagulation. Subsequently, an angiocatheter was inserted into the femoral artery,
proximal to the origin of the gastrocnemius muscle to allow for bolus tracer injection.
Additionally, a small shunt was placed in the femoral vein draining the gastrocnemius muscle
that allowed for diversion of flow into a port which facilitated sampling of the venous effluent.
Finally, a microcirculation flow probe (Transonic; 0.5/0.7 PS) was placed on the femoral
artery to monitor muscle perfusion.
Following completion of the surgical preparation and 30 minutes of self-perfused rest,
the muscle was stimulated via the sciatic nerve to contract for 3 minutes at either 3 or 5 Hz
isometric twitch contractions, separated by 15 minutes of self-perfused rest. Muscle tension
development and blood flow were monitored continuously, and arterial and venous blood
aliquots were taken within the final 30 seconds for the determination of blood gas content.
Upon completion of the contraction protocols, the gastrocnemius muscle was allowed
at least 20 minutes of rest for full recovery. At this point, 20 l of

I-albumin (10 Ci;
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Perkin-Elmer, Shelton, CT) was injected as a spike bolus (injection time <0.5 s) into the
arterial angiocatheter and venous effluent samples were collected at a rate of 1/s for the
subsequent 35 seconds. Venous effluent samples were then immediately transferred into
silicate tubes and placed into a gamma counter for activity determination. In order to assess
the potential for leakage of the labeled albumin from the intravascular space as a source
for error, the gastrocnemius muscle was cleared by perfusion with PSS following
euthanasia. Subsequent to a determination of mass, the muscle was placed in the counter
for determination of residual activity. Residual activity within the gastrocnemius muscle
did not exceed 200 cpm/animal, a level that was far lower than those determined in the
venous blood aliquots.
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Mathematical Analyses of Results: Arteriolar perfusion in both parent and daughter vessels
within in situ cremaster muscle of LZR and OZR was calculated as:

Q = (V  1.6 −1 )(r 2 )(0.001)

Equation 1

where Q represents arteriolar perfusion (nl•s-1), V represents the measured red cell
velocity from the optical Doppler velocimeter (mm•s-1; with V/1.6 representing an
estimated average velocity assuming a parabolic flow profile; Ref. 10), and r represents
arteriolar radius (m; Ref. 3).
The total volume perfusion in the daughter arterioles was determined as the sum of
the individual perfusion rates, and the proportion of flow within each was determined as the
quotient of the individual branch divided by the total.  is defined as the ratio of the greater
of the two flows in the daughter vessel to the total flow in the parent vessel. As an example,
if flow distribution was homogeneous between daughters,  for that bifurcation would be 0.5
in both daughter arterioles, while if the proportion of flow in one daughter arteriole was 60%,
 for that bifurcation would be 0.6, with flow distribution being 0.6 in the ‘high perfusion’
arteriole and 0.4 in the ‘low perfusion’ arteriole (13). For the present study, following the
initial determination of  (described above) we determined the changes in  every 20 seconds
over the subsequent 5-minute period.
The dilator or constrictor responses of ex vivo microvessels or aortic rings following
agonist challenge were fit with the three-parameter logistic equation:

 max − min 
y = min + 
log ED50 −x 
1 + 10


Equation 2

where y represents the change in arteriolar diameter, “min” and “max” represent the
lower and upper bounds, respectively, of the change in diameter or tension with increasing
agonist concentration, x is the logarithm of the agonist concentration, and log ED50
represents the logarithm of the agonist concentration ( x ) at which the response ( y ) is
halfway between the lower and upper bounds.
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Vascular NO bioavailability measurements were fit with a linear regression equation:
y =  0 + 1 x

Equation 3

where y represents the NO concentration, ∝0 represents an intercept term, 𝛽1
represents the slope of the relationship, and 𝑥 represents the log molar concentration of
methacholine.
The determination of passive arteriolar wall mechanics (used as indicators of
structural alterations to the individual microvessel) are based on those used previously (5),
with minor modification.

For the calculation of circumferential stress, intraluminal

pressure was converted from mmHg to N/m2, where 1 mmHg=1.334102 N/m2.
Circumferential stress () was then calculated as:

 = (PIL  ID ) (2WT )

Equation 4

where ID represents arteriolar inner diameter (m), and WT represents wall thickness (m)
at that intraluminal pressure (PIL). Circumferential strain () was calculated as:

 = (ID − ID5 ) ID

Equation 5
5

where ID5 represents the internal arteriolar diameter at the lowest intraluminal pressure
(i.e., 5 mmHg).
The stress versus strain relationship from each vessel was fit (ordinary least squares
analyses, r2>0.85) with the following exponential equation:

 =  5 e 

Equation 6

where 5 represents circumferential stress at ID5 and  is the slope coefficient describing
arterial stiffness. Higher levels of  are indicative of increasing arterial stiffness (i.e.,
requiring a greater degree of distending pressure to achieve a given level of wall
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deformation).
In specific experiments, 200 l blood samples were drawn from the carotid artery
cannula and femoral vein angiocatheter immediately prior to and following completion of, the
muscle contraction periods. Samples were stored on ice until they were processed for blood
gas pressures, percent oxygen saturation and hemoglobin concentration using a Corning
Rapidlab 248 blood gas analyzer. Muscle perfusion, arterial pressure, and bulk blood flow
through the femoral artery were monitored for one minute prior to muscle contractions and
throughout the contraction period using a Biopac MP150 with Acqknowledge data acquisition
software at a 50Hz sampling frequency. Muscle perfusion and performance data after three
minutes of contraction were normalized to gastrocnemius mass, which was not different
between LZR (2.180.09 g) and OZR (2.060.10 g). Oxygen content within the blood
samples was determined using the following standard equation:
C x O2 = (1.39  [ Hb ]  %SatO2 ) + (0.003  Px O2 )

Equation 7

Where CxO2 and PxO2 represent the total content (ml/dL) or partial pressure of oxygen
(mmHg), respectively, of arterial or venous blood (denoted simply as ‘x’). [Hb] represents
hemoglobin concentration within the blood sample (g/dL); %O2Sat represents the percentage
oxygen saturation of the hemoglobin and 1.39 and 0.003 represent constants describing the
amounts of bound and dissolved oxygen in blood. Oxygen uptake across the gastrocnemius
muscle was calculated using the Fick equation:
VO2 = Q  (CaO2 − CvO2 )

Equation 8

where VO2 represents oxygen uptake by the gastrocnemius muscle, Q represents femoral
artery blood flow (ml/g/min), and CaO2 and CvO2 represent arterial and venous oxygen
content, respectively.
Analyses of Tracer Washout Curves:

For the
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I-albumin washout, four standard

parameters describing characteristics of tracer washout curves, including mean transit time
( t ), relative dispersion (RD), skewness ( 1 ), and kurtosis (  2 ), were computed as
functions of the transport function h(t) (4). As described in our recent study (17), the tails
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of the tracer washout curves were extrapolated in the form of single exponential time course
to allow for computing the four parameters by the integration for sufficiently long time for
convergence (21). In this study, experimentally-measured time courses are extrapolated to
100 seconds, at which C(t) is estimated to be less than 10-9 of the maximum washout tracer
activity. The transport function h(t) is estimated from



h(t ) = C(t )



0

C(t )dt

Equation 9

where C(t) is the time course of activity of intravascular tracer in outlet flow exiting the
collecting tube. The mean transit time t is calculated from experimentally measured
washout curves according to:


t =  t  h(t )dt

Equation 10

0

The RD of h(t) is a measure of the relative temporal spread of h(t) and computed as the
ratio of standard deviation of h(t) to the mean transit time from:
1/ 2

2
 

RD =   ( t − t )  h(t )dt 
0



/t

Equation 11

The skewness ( 1 ) is a measure of asymmetry of h(t) and computed from:

1 = 



0

(t − t )

3

 
 h(t )dt   ( t − t
 0

)

2


 h(t )dt 


3/ 2

Equation 12

Skewness is a measure of the asymmetry of the perfusion distribution. In other words, it
is a measure of the extent to which the perfusion distribution is skewed (as opposed to
simply being shifted) to higher or lower values of perfusion. The kurtosis (  2 ) is a measure
of deviation of h(t) from a normal distribution and computed from:

2 = 



0

(t − t )

4

 
 h(t )dt   ( t − t
 0
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)

2


 h(t )dt 


4/2

−3

Equation 13

Kurtosis is a measure of the “sharpness of the peak” of the perfusion distribution. The
familiar Gaussian bell-shaped curve has 2 = 0; positive values of 2 indicate a sharper
peak than a Gaussian. The four parameters are estimated based on the above equations for
each animal in each experimental group.
Determining the Effectiveness of Interventions:

The effectiveness of the chronic

interventions at improving specific biological outcomes (e.g., biomarkers, vascular function,
behavioral scores, etc.) were calculated as:
 ABS (OZR Intervention − OZRControl ) 

 100
 ABS (OZRControl − LZRControl ) 

Equation 14

where LZRControl and OZRControl represent the values of the measured parameter under
untreated control conditions and OZRIntervention represents the values of the measured
parameter as a result of chronic imposition of a given intervention under age-matched
conditions. This determines the % recovery in a parameter from the control condition in
OZR, back to that in control LZR, as a result of the specific intervention.
Statistical Analyses of Results: All data are presented as mean±SE. Statistically
significant differences in measured physiological parameters (e.g., arterial pressure, blood
flow, microvessel density), calculated physiological parameters (e.g., slope coefficients,
upper or lower bounds), measurements of plasma biomarkers, were determined using
analysis of variance (ANOVA). In all cases, Student-Newman-Keuls post hoc test was used
when appropriate and p<0.05 was taken to reflect statistical significance.
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4.4 Results
Table 1 presents data describing the baseline and systemic characteristics of the
animal groups used in the present study. By 13 weeks of age, OZR were already
manifesting multiple elements of the metabolic syndrome as compared to LZR, including
significant elevations in body mass, plasma insulin and glucose levels, dyslipidemia and
markers of oxidant stress and inflammation. These differences between LZR and OZR
were exacerbated by 20 weeks of age, with a significant elevation in blood pressure as well.
While single treatment with either atorvastatin or exercise was able to improve specific
markers of the metabolic syndrome over the duration of the treatment, simultaneous
imposition of both treatments was of greater effectiveness in terms of restoring the
metabolic profile to that presented in control LZR.
Table 1. Data (mean±SE) describing the baseline conditions of the animals under the conditions of the present study.
The data in the parentheses represents the extent to which the relevant intervention restored the normal level of the
parameter. Please see text for details. * p<0.05 vs. LZR at that age; † p<0.05 vs. OZR at that age.
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(Table 1 continued)

Figure 1 summarizes the data describing the dilator reactivity of ex vivo gracilis
muscle resistance arterioles in response to increasing concentrations of acetylcholine in the
present study. As compared to responses in LZR, dilator reactivity in arterioles of OZR at
13 weeks to acetylcholine was significantly reduced (Panel A). Acute treatment of the
vessels with TEMPOL had minimal impact on responses in LZR, but improved reactivity
in OZR arterioles. By 20 weeks of age, the difference in acetylcholine-induced reactivity
was pronounced between LZR and OZR (Panel B). While chronic treatment with ATOR
or EXER improved responses to acetylcholine in OZR; the combination of the two
treatments resulted in the greatest restoration of dilator responses.

Panel C presents data

describing the impact of acute treatment with TEMPOL on the acetylcholine-induced
gracilis arteriolar dilation in all groups of rats at 20 weeks. While TEMPOL had negligible
impact on responses in vessels from LZR, and the greatest impact on dilator responses in
vessels from OZR, the impact on responses in arterioles from OZR that had been treated
with ATOR, EXER or both were blunted as compared to that in untreated OZR. The ability
of the chronic interventions to restore normal dilator reactivity (determined in LZR) from
the maximum impairment (determined in OZR) are presented in Panel D. While both
ATOR and EXER resulted in a significant restoration of normal function in OZR, with a
significant additive benefit of acute TEMPOL treatment, the combination of both
interventions resulted in the greatest degree of recovery in acetylcholine-induced responses
with the smallest additional benefit from an acute treatment with the antioxidant.
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Figure 1. Data (mean±SE) describing the dilator reactivity of ex vivo gracilis muscle resistance arterioles in response to
increasing concentrations of acetylcholine. Panel A: data from LZR and OZR at 13 weeks of age under untreated
conditions and following acute treatment with the antioxidant TEMPOL. Panel B: data from LZR and OZR at 20 weeks
of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or
both concurrently. Panel C: the change in the upper bound of the logistic equation fit to the curves in Panel B following
acute treatment with the antioxidant TEMPOL. Panel D: the extent to which the different interventions restored normal
function, and the additive benefit of acute treatment with TEMPOL. n=6 for all groups. For Panels A-C: * p<0.05 vs.
LZR; † p<0.05 vs. OZR, For Panel D: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER.
Please see text for details.

Dilator responses of gracilis arterioles in response to hypoxia from LZR and OZR
at 13 weeks are summarized in Figure 2, Panel A. Hypoxic dilation in vessels from OZR
was significantly reduced as compared to that in LZR, although acute treatment of the
vessel with TEMPOL improved responses in vessels from OZR only. By 20 weeks, the
impaired hypoxic dilation in arterioles from OZR was exacerbated, and chronic treatments
with EXER or ATOR+EXER resulted in significant improvements (ATOR alone did not
significantly improve responses; Panel B). Acute treatment of gracilis arterioles from the
groups of rats at 20 weeks of age with TEMPOL had a significant impact on hypoxic
dilation in untreated OZR and in OZR treated with chronic ATOR or EXER only (Panel
C), while the effectiveness of the interventions on restoring normal function was similar
between ATOR and EXER, with the combination of both being most effective, the
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additional benefit of acute TEMPOL treatment was lowest in the ATOR+EXER group
(Panel D).

Figure 2. Data (mean±SE) describing the dilator reactivity of ex vivo gracilis muscle resistance arterioles in response to
reduced PO2 in the chamber (hypoxia). Panel A: data from LZR and OZR at 13 weeks of age under untreated conditions
and following acute treatment with the antioxidant TEMPOL. Panel B: data from LZR and OZR at 20 weeks of age
under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or both
concurrently. Panel C: the change in the dilator response in Panel B following acute treatment with the antioxidant
TEMPOL. Panel D: the extent to which the different interventions restored normal function, and the additive benefit of
acute treatment with TEMPOL. n=6 for all groups. For Panels A-C: * p<0.05 vs. LZR; † p<0.05 vs. OZR, For Panel D:
* p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER. Please see text for details.

The constriction of ex vivo skeletal muscle resistance arterioles in 13-week old LZR
and OZR following in response to increasing concentrations of norepinephrine is presented
in Figure 3, Panel A. At this age, there was no difference in vasoconstriction to increasing
concentrations of the adrenergic agonist between groups. However, by 20 weeks of age
(Panel B), constrictor responses to norepinephrine were significantly greater in OZR vs.
LZR, and this difference in reactivity was nearly abolished by chronic treatment with
ATOR, EXER or both.

Acute treatment of these groups with TEMPOL improved

responses in untreated OZR but had minimal impact on constrictor reactivity of gracilis
arterioles from all other groups (Panel C). The extent to which chronic ATOR, EXER or
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both interventions restored normal norepinephrine-induced reactivity is summarized in
Panel D. As compared to OZR at 20 weeks, chronic imposition of all three interventions
resulted in an excellent recovery to normal constriction to norepinephrine, with minimal
added benefit from acute treatment with TEMPOL.

Figure 3. Data (mean±SE) describing the constrictor reactivity of ex vivo gracilis muscle resistance arterioles in response
to increasing concentrations of norepinephrine. Panel A: data from LZR and OZR at 13 weeks of age under untreated
conditions and following acute treatment with the antioxidant TEMPOL. Panel B: data from LZR and OZR at 20 weeks
of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or
both concurrently. Panel C: the change in the lower bound of the logistic equation fit to the curves in Panel B following
acute treatment with the antioxidant TEMPOL. Panel D: the extent to which the different interventions restored normal
function, and the additive benefit of acute treatment with TEMPOL. n=6 for all groups. For Panels A-C: * p<0.05 vs.
LZR; † p<0.05 vs. OZR, For Panel D: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER.
Please see text for details.

The dilator response of proximal in situ cremasteric arterioles to increasing
concentrations of acetylcholine in LZR and OZR at 13 weeks of age are presented in Figure
4, Panel A, where responses were significantly reduced in vessels in OZR, and this
difference was largely abolished following treatment of the cremaster muscle with
TEMPOL. In OZR at 20 weeks, while the differences in acetylcholine-induced dilation
with LZR were increased, chronic imposition of ATOR, EXER or both significantly
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improved responses (Panel B) and reduced the beneficial impact of acute TEMPOL
treatment on dilator reactivity (Panel C). Additionally, chronic imposition of ATOR,
EXER or both from 13 weeks of age (with ‘both’ being most effective), significantly
restored normal vascular reactivity to increasing concentrations of acetylcholine (Panel D).
For distal arterioles of in situ cremaster muscle, the patterns in the data were extremely
similar to those for proximal arterioles (data not shown).

Figure 4. Data (mean±SE) describing the dilator reactivity of in situ cremaster muscle resistance arterioles in response
to increasing concentrations of acetylcholine. Panel A: data from LZR and OZR at 13 weeks of age under untreated
conditions and following acute treatment with the antioxidant TEMPOL. Panel B: data from LZR and OZR at 20 weeks
of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or
both concurrently. Panel C: the change in the upper bound of the logistic equation fit to the curves in Panel B following
acute treatment with the antioxidant TEMPOL. Panel D: the extent to which the different interventions restored normal
function, and the additive benefit of acute treatment with TEMPOL. n=6 for all groups. For Panels A-C: * p<0.05 vs.
LZR; † p<0.05 vs. OZR, For Panel D: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER.
Please see text for details.

Figure 5 presents the data describing the changes in constrictor responses to
increasing concentrations of norepinephrine for in situ cremasteric arterioles. While there
were minimal differences in responses at 13 weeks of age between strains (Panel A), the
differences at 20 weeks of age were somewhat more extensive, there were no differences
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in reactivity that were demonstrated to be consistently statistically significant (Panel B).
As above, for distal arterioles of in situ cremaster muscle, the norepinephrine-induced
constriction, while potent, did not demonstrate statistically significant differences between
LZR and OZR at either age range as such, have not been formally presented (data not
shown).

Figure 5. Data (mean±SE) describing the constrictor reactivity of in situ cremaster muscle resistance arterioles in
response to increasing concentrations of norepinephrine. Panel A: data from LZR and OZR at 13 weeks of age under
untreated conditions and following acute treatment with the antioxidant TEMPOL. Panel B: data from LZR and OZR at
20 weeks of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise
(EXER) or both concurrently. n=6 for all groups.

The impact of chronic interventions on the reversibility of altered wall mechanics
in LZR and OZR gracilis arterioles are summarized in Figure 6. At 13 weeks of age, there
were no significant differences in the inner diameter of gracilis arterioles (Panel A), their
incremental distensibility (Panel C) or the slope () coefficient from their stress versus
strain relationship (Panel E). By 20 weeks of age, arterioles from OZR exhibited a reduced
passive inner diameter as compared to those from LZR (Panel B), with a reduced
incremental distensibility (Panel D) and a significant left-shifting of the stress versus strain
relationship (Panel F).

Chronic interventions with ATOR and EXER, alone or in

combination, were largely ineffective at blunting this effect (Panel G).
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Figure 6. The mechanics of the wall of ex vivo gracilis muscle resistance arterioles under Ca2+-free conditions with
increasing intralumenal pressure. Data are presented as mean±SE. Panel A: inner diameter of gracilis muscle resistance
arterioles from LZR and OZR at 13 weeks. Panel B: inner diameter of gracilis muscle resistance arterioles from LZR
and OZR at 20 weeks under control conditions and in response to 7 weeks of intervention with atorvastatin (ATOR),
exercise (EXER) or both concurrently. Panel C: incremental distensibility of gracilis arterioles from LZR and OZR at
13 weeks. Panel D: incremental distensibility of gracilis arterioles from LZR and OZR at 20 weeks under control
conditions and in response to 7 weeks of intervention with ATOR, EXER or both. Panel E: circumferential stress versus
strain relationship between gracilis arterioles from LZR and OZR at 13 weeks with the determination of the slope ( )
coefficient. Panel F: stress versus strain relationship between gracilis arterioles from LZR and OZR at 20 weeks under
control conditions and in response to 7 weeks of intervention with ATOR, EXER or both with the determination of the
slope ( ) coefficient. n=6 for all groups. * p<0.05 vs. LZR; † p<0.05 vs. OZR. Please see text for details.
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Figure 7 presents data describing the gastrocnemius muscle microvessel density
(Panel A) and the extent of recovery in MVD as a result of the chronic interventions (Panel
B) in LZR and OZR. At 13 weeks of age, there was a reduction in MVD between LZR
and OZR, which became much more pronounced by 20 weeks of age. This difference was
largely unaffected by chronic treatment with ATOR and only marginally affected by
chronic EXER from 13 weeks of age in OZR. However, combined imposition of both
interventions resulted in a significant improvement in skeletal muscle MVD in OZR.

Figure 7. Microvessel density within gastrocnemius muscle of LZR and OZR under the conditions of the present study.
Data (mean±SE) are presented for animals at 13 weeks of age and at 20 weeks of age under control (untreated) conditions
and in response to 7 weeks of ATOR, EXER or both interventions imposed concurrently (Panel A). Panel B presents the
extent to which the different chronic interventions restored normal levels of microvessel density in OZR. n=6 for all
groups. Panel A: * p<0.05 vs. LZR; † p<0.05 vs. OZR. Panel B: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡
p<0.05 vs. OZR EXER. Please see text for details.

Data describing the perfusion distribution coefficient (), in both the proximal
(Panel A) and distal (Panel B) cremasteric microcirculation are summarized in Figure 8.
These data suggest that there were minimal differences in the average magnitude of 
between LZR and OZR at 13 weeks of age, although the temporal variability in  over the
data collection window was reduced in OZR. In contrast,  was increased, and its
variability reduced, in OZR at 20 weeks of age versus LZR, and chronic imposition of
ATOR, EXER or both from 13 weeks of age resulted in improvements to  and a greater
degree of variability as compared to responses in untreated OZR. These results were
consistent in both proximal (Panel A) and distal (Panel B) arteriolar bifurcations within the
cremasteric microcirculation.
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Figure 8. Perfusion heterogeneity () at proximal (~70 m diameter; Panel A) and distal (~30 m diameter; Panel B)
arteriolar bifurcations within in situ cremaster muscle of LZR and OZR under the conditions of the present study. Data
(mean±SE) are presented for animals at 13 weeks of age and at 20 weeks of age under control (untreated) conditions and
in response to 7 weeks of ATOR, EXER or both interventions imposed concurrently (Panel A). n=6 for all groups. *
p<0.05 between variability in group vs. LZR variability; † p<0.05 between variability in this group vs. OZR variability.
Please see text for details.

Figure 9 summarizes the bioavailability of vasoactive metabolites that have been
previously demonstrated to play a contributing role in the vascular phenotypes discussed
above. Vascular nitric oxide bioavailability (Panel A) was reduced in arteries of OZR as
compared to that in LZR at 13 weeks, and this was exacerbated by 20 weeks. Chronic
intervention with ATOR, EXER or both resulted in a significant improvement in levels of
NO bioavailability at 20 weeks of age in OZR. Vascular hydrogen peroxide levels,
elevated in arteries of OZR versus LZR at 20 weeks of age (Panel B), demonstrated a higher
degree of variability and, although presenting a mirrored trend as compared to NO, did not
produce a consistently significant outcome subsequent to the interventions. A similar
pattern to that for NO was determined for PGI2 bioavailability (Panel C), although the
ability of the interventions to restore normal levels was less robust. Conversely, TxA2
bioavailability (Panel D) was significantly increased by 13 weeks of age in arteries of OZR
as compared to that in LZR, and this elevation was only reduced at 20 weeks following
combined imposition of ATOR and EXER from 13 weeks of age in OZR.
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Figure 9. Data describing the bioavailability of signaling molecules associated with healthy and impaired vascular
function. Data (mean±SE) are presented for the bioavailability of nitric oxide (NO, Panel A), hydrogen peroxide (H2O2,
Panel B), prostacyclin (PGI2, Panel C) and thromboxane A2 (TxA2, Panel D). n=6 for all groups. * p<0.05 vs. LZR; †
p<0.05 vs. OZR. Please see text for details.

The results of the in-situ gastrocnemius muscle performance experiments are
summarized in Figure 10. At 13 weeks of age OZR demonstrated an accelerated muscle
fatigue rate as compared to LZR after 3 minutes of contraction at both 3Hz an 5Hz
(isometric twitches), with the difference being exacerbated at 5Hz (Panel A). This
impaired muscle performance was increased at 20 weeks of age, and was not significantly
impacted by ATOR or EXER, but only in response to the combination intervention. The
functional hyperemic response to muscle contraction was similar between LZR and OZR
at 13 weeks but was attenuated by 20 weeks for both 3Hz and 5Hz contractions (Panel B).
All three interventions were successful at significantly improving the bulk hyperemic
response to both levels of increased metabolic demand following chronic intervention from
13 weeks. Oxygen extraction (Panel C) and VO2 (Panel D) across the muscle, while
comparable in LZR and OZR at 13 weeks, were reduced by 20 weeks of age. While ATOR
and EXER alone resulted in mild improvements that were not statistically significant for
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extraction of VO2, the combination of the two interventions restored both parameters to
levels that were not significantly different from that in LZR (at 3Hz only).

Figure 10. Vascular responses and contractile performance of in situ skeletal muscle of LZR and OZR at 13 weeks of age
and at 20 weeks of age under control (untreated) conditions and in response to 7 weeks of intervention with atorvastatin
(ATOR), treadmill exercise (EXER) or both concurrently. Data (mean±SE) are presented from the animal groups in response
to three minutes of muscle contraction at 3 or 5Hz (isometric twitch). Data are presented for the percentage of the peak force
development after three minutes of the contraction bout (Panel A), the hyperemic responses to muscle contraction (Panel B),
oxygen extraction across the gastrocnemius muscle (Panel C), and oxygen consumption across the gastrocnemius muscle
(Panel D). n=6 for all groups. * p<0.05 vs. LZR; † p<0.05 vs. OZR. Please see text for details.

Figure 11 presents data describing the average tracer washout from the in situ
gastrocnemius preparation under rest conditions across the different experiment groups of
the present study. The appearance of
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I-albumin in the venous effluent draining the

gastrocnemius muscle in all groups in the present study is represented in Panel A. Figure
12 summarizes data describing the aggregate washout curves. Mean transit time of the
tracer across the gastrocnemius was very similar across all groups, suggesting that the
relationship between bulk blood flow to the gastrocnemius muscle and vascular volume in
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the different groups was not significantly different in the present study (Panel A). The
relative dispersion of tracer across the muscle (RD; Panel B) was elevated in untreated
OZR at 20 weeks of age as compared to all other groups, suggestive of an increased
perfusion heterogeneity throughout the microcirculation of the gastrocnemius muscle.
While treatment with ATOR was ineffective at restoring RD, chronic exercise, alone or in
combination with ATOR, was superior at restoring RD toward levels determined in agematched LZR. Both the skewness (Panel C) and the kurtosis (Panel D) of the tracer
washout curves were reduced in OZR as compared to age-matched LZR, and these shifts
in the washout patterns were improved toward that determined in LZR as a result of either

Venous Effluent Activity (cpm)

ATOR, EXER or both interventions imposed concurrently.
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Figure 11. Data describing the tracer washout of 125I-albumin from the in situ gastrocnemius muscle of LZR and OZR
under the conditions of the present study. Data (mean±SE) are presented for LZR and OZR at 13 weeks of age and at 20
weeks of age under control (untreated) conditions and in response to 7 weeks of intervention with atorvastatin (ATOR),
treadmill exercise (EXER) or both concurrently. Please see text for details; n=5 for each group.
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Figure 12. Data (presented as mean±SE) describing the four moments of the washout of 125I-albumin from the in situ
gastrocnemius muscle for LZR and OZR at 13 weeks of age and at 20 weeks of age under control (untreated) conditions and
in response to 7 weeks of intervention with atorvastatin (ATOR), treadmill exercise (EXER) or both concurrently. Data are
shown for the mean transit time of the washout (Panel A), the relative dispersion of the washout (RD; Panel B), the distribution
skewness (Panel C) and kurtosis (Panel D). Please see text for details; n=5 for each. * p<0.05 vs. LZR; † p<0.05 vs. OZR.
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4.5 Discussion
The powerful association between chronic metabolic disease and the increased risk
for the development of PVD has been well known for many years. While there have been
many studies seeking to understand the mechanisms underlying the compromised vascular
function under these conditions, or how interventional strategies could serve to blunt the
development of the poor vascular outcomes (please see Ref. 33 for a recent review), an
understanding of the outright reversibility of established vasculopathy in translationally
relevant models has been more elusive. This is particularly troubling, as it is this challenge
which is most clinically relevant, where patients present themselves in a clinical setting
only once they have already experienced the manifestations of PVD (e.g., rapid muscle
fatigue, pain upon exertion, etc.). The purpose of this study was to use the OZR model of
the metabolic syndrome, at an age where impairments to skeletal muscle microvascular
structure and function have already been established, and where impairments to hyperemic
responses and muscle performance are still mild, to determine the extent to which
clinically-relevant interventions could improve not only microvascular reactivity and
structure, but also muscle fatigue and hyperemia with increased metabolic demand.
At 13 weeks of age, the presence of the metabolic disease in OZR was associated
with impaired endothelial function, reduced microvessel density and initial evidence of
impaired muscle performance and active hyperemic responses.

As severity of the

metabolic syndrome progressed, impairments to microvascular structure and function
increased to include an increased stiffening of the arteriolar wall, an increasing (and
increasingly stable) heterogeneity of perfusion at arteriolar bifurcations and a worsening
of skeletal muscle perfusion and oxygen exchange. While this is not novel information
and has been described previously, it does set the appropriate context for the present study:
the vasculopathy associated with the metabolic syndrome at 13 weeks of age was present,
was sufficient to impact skeletal muscle performance, and continued to evolve naturally
over the subsequent 7 weeks to further compromise muscle blood flow and performance.
Chronic ingestion of atorvastatin from 13 weeks of age or chronic imposition of
treadmill exercise demonstrated some effectiveness at improving vascular, and by
extension muscle blood flow and performance, outcomes in OZR as compared to no
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intervention, but even the combination of the two had clear limits on effectiveness. Under
all three interventions, with the combination of both atorvastatin and exercise being most
effective, the improvement to the vasoactive metabolite profile – associated with the
improvement in oxidant stress and inflammation levels – was critical for improving
vascular reactivity to acetylcholine, hypoxia and norepinephrine. In addition, there were
some improvements to microvessel density, although the extent of the rarefaction even
with the combined interventions remained considerable in the OZR despite 7 weeks of
aggressive treatment. Further, there was very little change in the progression of altered
wall mechanics in the arterioles of OZR, regardless of intervention.
While the structure of the microvascular networks was resistant to improvement
following intervention, there was an improvement in both the magnitude and in the
variability of  throughout the microcirculation of OZR with chronic atorvastatin, exercise
or both. This was evident in both the direct observations of the microvascular networks in
the cremaster or using the tracer washout curve analyses for the labeled albumin. These
results suggest that the increased heterogeneity of perfusion distribution that accompanies
progressive metabolic disease in OZR can be partially reversed with aggressive
intervention, even with established dysfunction. The combination of these improvements
to reactivity, and especially to perfusion distribution, was associated with improvements to
muscle performance, hyperemic responses and oxygen exchange for skeletal muscle in
OZR. However, as recovery was most clearly evident at 3Hz contraction, as it seemed that
5Hz contraction frequency have been too severe a challenge for any significant recovery
to have been evident.
A study of this scope and focus immediately lends itself to a wide array of
provocative questions, some of which we will attempt to address or clarify in the
succeeding paragraphs. Obviously, one question that immediately comes to mind is the
timing of the intervention and its duration. We elected to use 13 weeks of age for two
major reasons. First, the vasculopathy was established at this age and was beginning to
impact muscle blood flow and performance, so this was considered to be the earliest time
point that was relevant for “reversing” rather than for “blunting development” of vascular
dysfunction. Secondly, in preliminary studies, 15 weeks of age was also considered as an
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option for the initiation of intervention due to the greater establishment of vasculopathy.
However, it was rapidly determined that the exercise intervention was not feasible as OZR
at that age were not able to consistently exercise without invoking a level of attrition that
made the experiments unrealistic.
The use of the 7 weeks of intervention was selected for two reasons as well. First,
using a 4-week intervention, which would bring animals to the ~17-week age range we
have employed historically, was not considered to of sufficient duration to determine any
meaningful outcome. Second, using a 7-week intervention duration brings us to a 20-week
old OZR, which we have determined is the maximum age we have been able to employ
before changes to skeletal muscle function (e.g., Ca2+ handling, half relaxation time,
maximal twitch tension, fiber type distribution) become too great to allow for an accurate
interpretation of the data.
The failure of arteriolar wall mechanics to demonstrate any significant
improvement with intervention or, given its lack of presence at 13 weeks of age in OZR,
could actually be considered as an appearance of the dysfunction despite the interventions,
was a particularly striking observation of the present study. While the mechanisms
underlying the progressive reduction in vascular wall distensibility with metabolic disease
(in OZR and in other models) are a continuing area of active investigation, it may be that
the combination of atorvastatin and exercise are simply “off target” for preventing vascular
wall remodeling. In our previous studies, the increased stiffness of the arteriolar wall in
OZR was associated more with the development of hypertension rather than with impaired
glycemic control or dyslipidemia (18), and previous studies using interventions specifically
targeted at reducing blood pressure have been more effective at moderating the changes to
vascular wall structure and mechanics (30).
The relatively modest responses at improving microvessel density are also
intriguing, as previous studies have clearly demonstrated that chronic atorvastatin
treatment and/or exercise from a relatively young age and severity of the metabolic
syndrome was effective at blunting rarefaction severity in skeletal muscle of OZR (14).
However, it seems plausible that the use of the 13 week age for the start of intervention,
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while justifiable from the perspective of translational relevance, may have missed the
window when the extent of rarefaction is most modifiable. In a recent study examining the
temporal nature and mechanistic bases of rarefaction in skeletal muscle of OZR, it was
evident that the initial phase of rarefaction occurs prior to 10-12 weeks of age in OZR and
was most closely predicted by the severity of both inflammation and vascular production
of TxA2 (14).

For maximal effectiveness, it was proposed that interventions against

rarefaction should be initiated prior to 10 weeks of age in OZR, although this is somewhat
problematic as there is no functional phenotype associated with these early changes to
microvessel density that has been identified. Regardless, it seems likely that the optimal
window for intervening against microvessel loss in skeletal muscle rarefaction in OZR may
have been missed with interventions starting only after 13 weeks of age. However, it must
be emphasized that we have only used a 7-week intervention duration. Whether a longer
duration of atorvastatin treatment, exercise regimen or both (or some other intervention),
would result in a greater degree of reversibility of the skeletal muscle microvascular
impairments will require dedicated study.
An additional issue that requires some comment is the observation that, while there
were significant improvements to the reactivity of arterioles from the gracilis muscle,
muted improvements to the microvessel density of the gastrocnemius muscle, and
improvements to the performance, blood flow, oxygen handling and tracer washout
kinetics indicative of a less heterogeneous perfusion distribution within the in situ
gastrocnemius muscle of OZR, this study also presents data describing the improvement to
the hemodynamic control of perfusion distribution in the in situ cremaster muscle – a tissue
that is not involved in the exercise training regimen and that does not directly benefit from
the effects of the chronic exercise (with or without concurrent atorvastatin therapy). This
provides strong support that the improved systemic effects of chronic exercise therapy in
OZR, which can include an improved endocrine, oxidant stress and pro-inflammation
status, can be highly effective in terms of improving vascular function and may work in
combination with direct effects in the exercising muscles of interest to produce a systemwide improvement to vascular health under conditions of the metabolic syndrome.
However, caution must be employed when interpreting some of the results of the present
study. The measurement of vascular metabolites that can impact the regulation of tone
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used larger arteries and not resistance arterioles. While this allowed us to reduce animal
number and provide insight into “within animal” comparisons, it must be remembered that
vascular environments are different between larger arteries and resistance arterioles, with
the potential for introducing inaccuracy in terms of assessing the importance of the
metabolites to tone regulation.
Given the results of the present study, it may be appropriate to speculate on not just
the effect of the interventions on the potential for reversibility of established vasculopathy
(or potential mechanisms), but also on whether the effects of these interventions can be
additive or potentially synergistic. It has been well established that both ATOR and EXER
can improve anti-inflammatory and anti-oxidant capacity, thereby improving vascular
function and health outcomes through those mechanistic pathways. However, results from
the present study suggest that this effect is more diverse than a single issue, such as
improved nitric oxide bioavailability and may also include a partial restoration of vascular
arachidonic acid metabolism. This beneficial effect appears to be localized primarily to
the endothelial cell as responses vascular smooth muscle-dependent stimuli were largely
unaffected.

Further, over the time course of the present study, the impacts of the

interventions did not significantly reverse vascular structure, either at the individual vessel
or whole network levels of resolution.

While it is possible that a longer duration

intervention might improve the structural characteristics of the vasculature, we may simply
have intervened outside of the most appropriate window of time to elicit a beneficial
outcome (14).

Regardless, although the design of the current study does not allow for a

rigorous assessment of whether the interventions were additive or synergistic at this time,
it is clear that the combination therapy is sufficiently robust that it helps to restore not just
hyperemic responses and muscle fatigue rates, but also perfusion distribution, and thus O2
delivery, patterns within the skeletal muscle.
In summary, the results of the present study provide compelling evidence that the
imposition of two clinically-relevant interventions (atorvastatin and chronic exercise),
alone or in combination to an OZR with a pre-existing established vasculopathy can result
in improvements to specific indices of vascular reactivity, hemodynamics, blood flow,
oxygen handling and muscle performance. Further, these improvements appear to be
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clearly tied to the effects of both interventions on enhancing oxidant stress and proinflammation severity system-wide. The use of statins has been shown to result in
improved patency and limb salvage rates in patients undergoing revascularization for limb
ischemia (1). The specific mechanisms underlying this effect remain unclear. Perhaps these
improvements in microvascular dysfunction observed in this animal model help to explain
this clinical association in humans.

Indices of altered vascular structure, both at the

individual vessel and whole network levels of resolution were more resistant to
reversibility with the selected interventions and their duration, although determining if this
represents specific procedural issues with the present study or simply processes that are
more difficult to reverse will require further investigation. Regardless, the results of the
present study provide compelling insight and provocative direction for future study into
the reversibility of established vasculopathies under condition of chronic metabolic disease
and may have implications for primary and secondary prevention of PVD.
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Chapter 5

5

Thesis Conclusion
Approximately 20% of the adult population is afflicted with Metabolic Syndrome

(METS; Riediger & Clara, 2011) which is the presentation of obesity, dyslipidemia,
hypertension, and insulin resistance. METS increases the risk of cardiovascular disease
(CVD) by 2.6-fold and type 2 diabetes mellitus (T2DB) by 5-fold (Lakka, 2002).
Additionally, almost 40% of adults with METS over the age of 40 are afflicted with
peripheral vascular disease (PVD), the presentation of poor skeletal muscle blood
perfusion with increases in metabolic demand (Sumner et al., 2012). Thus, this perfusiondemand mismatch typically gives rise to increases in muscle fatigue and pain during
times of increased physical activity (Abdulhannan et al., 2012). The purpose of this
dissertation is to generate novel insights for both venular and arteriolar microvasculopathies using the translational animal model for METS, the obese Zucker rat
(OZR), and to investigate the potential reversibility of established PVD using exercise
and atorvastatin.
Chapter 1: Altered Postcapillary and Collecting Venular Reactivity in Skeletal Muscle
with Metabolic Syndrome
Retinal microcirculation studies have provided insight to alterations in venular
function with METS and how the control of venular diameter and venular network
structure can be significantly impacted (Lammert et al., 2012). While there are some
studies dedicated to venular function in the context of leukocyte interactions within the
venular walls in inflammation (Iba et al., 2012), there is limited information pertaining to
these dysfunctions in relevant animal models for METS and PVD. These experiments
sought to identify any alterations in postcapillary and collecting venule function in the
OZR compared to healthy controls.
The OZR presented with impaired dilator reactivity in both postcapillary and
collecting venules which was attributed to elevations in reactive oxygen species and its
negative effects on venular nitric oxide and prostacyclin bioavailability. Further,
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elevation in adrenergic and thromboxane A2 constrictor responses may contribute to the
impaired dilator responses. Taken together, these disparities indicated an altered
microvascular reactivity at the venular level of skeletal muscle, thereby providing insight
to an area of METS vasculopathy which has received little investment. Where this fits in
the context of METS microcirculatory research, as a whole, is a starting point for
potential, compelling avenues of future research. Previous studies have shown some of
the earlier, measurable changes to the microcirculation occur on the venular side (with
respect to leukocyte rolling and adhesion) in METS. The current study shows apparent
differences in vascular reactivities, with METS risk factors, which favor that of a more
vasoconstrictive state. While it is known that venules and veins do not necessarily change
resistance to restrict blood flow, but rather compliance to facilitate it (Rothe, 1983).
Therefore, the speculation can be made that the observable differences may be either an
adaptation to the existing microvasculapathies or a potential contributor to their severity.
Nevertheless, the changes are apparent and additional, dedicated studies are required to
further investigate these changes with respect to identifying the nature of their existence.

Chapter 2: Altered Distribution of Adrenergic Constrictor Responses Contributes to
Skeletal Muscle Perfusion Abnormalities in Metabolic Syndrome
Adrenergic traffic, signaling, and vascular responses may be elevated with METS
risk factors (Carlson et al., 2000; Naik et al, 2006; Frisbee 2004). Treatment with αadrenoreceptor antagonists equalizes the elevated blood pressure of the OZR to levels
comparable to healthy controls. However, it is unclear how general elevations in vascular
adrenergic output, which produces significant elevations in resistance, functions in vivo
to produce mild/moderate elevations in blood pressure observed in OZRs (Tofovic et al.,
1998; Frisbee, 2004). Therefore, these experiments sought to reveal potential contributors
of this disconnect using a multi-scale/resolution approach, thus garnering a greater
understanding of the impaired adrenergic control for PVD within METS.
The OZR experienced an increased α1 adrenoreceptor mediated, whole-animal
pressor response compared to healthy controls, independent of reactive oxygen species or
nitric oxide bioavailability. However, the blunted in situ hyperemic response in the OZR
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was mediated, in part, by reactive oxygen species (ROS) as the combination of TEMPOL
(ROS scavenger) and α1-adrenoreceptor inhibition elicited the greatest improvements in
muscle performance and volume of oxygen consumption. With a minor adjustment of the
classically used inclusion criteria for experiments of this nature, high resolution
interrogations of the in-situ cremaster muscle arterioles and ex vivo gracilis muscle artery
revealed an α1-adrenoreceptor mediated hyperresponsiveness with OZR vessels,
contributed to by ROS and nitric oxide bioavailability. Lastly, OZR arteriolar responses
to an α1 adrenoreceptor challenge revealed a more heterogeneous, constrictor response
compared to healthy controls. While these results support α1 adrenoreceptor as a key
contributor to the elevated pressor responses and vascular resistance in the OZR, the
purpose of a more heterogeneous response is unclear.
In the context of METS microvasculopathy research, it is well established αadrenoreceptor stimulated vasoconstrictor responses are elevated for subjects with METS
associated vascular dysfunction. Therefore, the current adrenergic literature emphasizes
investigation on biochemical signaling pathways and secondary messengers that may
contribute to the differences in response for the OZR versus healthy controls. While the
pathways are essential to understanding the underlying pathologies, it is critical we
continue to interrogate the functional outcomes of these pathologies as there are
important questions which remain unanswered. The current study, in part, provides
insight for the discrepancies of in vivo blood pressure responses and ex vivo vascular
responses observed with the OZR model. In doing so, changes in variance and frequency
distributions were coupled to these apparent differences in vascular response giving rise
to further questions. A speculative purpose for this phenomenon may include that of a
shift in initial tangential stresses due to changes in pressure and wall thickness in the
OZR vessels, thereby influencing vascular responses (described by Gore et al., 1972).
However, additional studies are necessary to explore this potential phenomenon.
Chapter 3: Chronic Atorvastatin and Exercise can Partially Reverse Established Skeletal
Muscle Microvasculopathy in Metabolic Syndrome
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The final set of experiments are dedicated to reversing established METS
associated vasculopathies of the skeletal muscle. Previous studies demonstrate a loss in
microvascular density (rarefaction) and function in parallel to the development of
metabolic syndrome (Machado et al., 2016). While there are interventional strategies to
decrease the severity of these vasculopathies, there is limited research on the restoration
or reversibility of vascular health following the onset of these vasculopathies.
Consequently, these experiments sought to determine the potential for reversibility or
restoration of established PVD using the chronic ingestion of an HMG-CoA inhibitor,
atorvastatin (ATOR), and/or the implementation of regular exercise (EXER).

In the current study, following the establishment of PVD at 13 weeks of age, a 7week intervention was implemented in which the ATOR group and EXER group
experienced significant improvements compared to time control OZRs while the
combination group of ATOR and EXER elicited the greatest degree of reversibility, in
certain criteria. There were favorable changes to vasoactive metabolite bioavailability,
reactivity, and perfusion distributions, thereby resulting in better muscle performance and
oxygen transport during stimulated muscle contractions compared to the time control
OZR group. With respect to the stated definition of reversibility, these improvements
were more comparable to the measured values of the healthy controls, indicating a
potential for reversibility of established PVD, within specific parameters.

While improvements to microvascular density were modest and there were no
significant improvements in wall mechanics, microvascular densities of the intervention
OZR groups did improve compared to the 20-week OZR time control. Those
improvements were comparable to the 13-week OZR time controls. This may be
interpreted as a blunting effect rather than restorable indicating a low potential for
reversibility. A lack of significant structural improvements may have resulted from
missing the appropriate interventional window (Frisbee et al., 2014) or potentially the
short duration of the intervention as Orr et al. reported improvements in the vessel
mechanics in humans following a 12-week ATOR intervention. However, the current
study using the OZR model is restricted to a narrow interventional window for an
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accurate assessment of established PVD (details in chapter 4 discussion; Orr et al., 2009).
Nevertheless, ATOR and EXER can significantly reverse specific indices of
microvascular function following established vasculopathy in the OZR thus representing
an effective avenue for interventions aimed at reversing microvasculopathies.

It is well established both forms of intervention possess anti-inflammatory and
anti-oxidant properties which can improve vascular health. Previous literature utilizing
both ATOR and EXER as primary and secondary (respectively) forms of treatment have
been shown to improve blood flow in health and with cardiovascular disease in humans.
Exercise has been shown to improve blood flow via mechanisms including increases in
eNOS expression, improved anti-oxidant systems, and decreases in NADPH oxidase
generated reactive oxygen species (Machado et al., 2016; Rush et al., 2003). Although the
mechanisms are unclear, ATOR has been shown to improve vascular outcomes for
inflammation related diseases by means of decreasing the expression of IL-6 and TNF-α,
decreasing CRP production, and upregulation of anti-oxidant systems (Rabkin et al.,
2013; Sodha et al., 2015). While speculation that a combination of these two treatment
methods elicit the greatest potential for PVD reversibility can be made, it is not known if
the improvements are synergistic or additive in a model for METS. Although the
existence of synergy between the two treatment methods has been shown in
atherosclerotic mice (Moustardas et al, 2014), the current study’s design does not allow
for such an assessment. Due to this, additional studies are required to garner a greater
understanding of the synergistic capacities for EXER and ATOR.
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